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Glossary of Abbreviations 29 
 30 
AVR  aortic valve replacement  31 
mAVR  minimal access aortic valve replacement 32 
BMI  body mass index 33 
CI  95% confidence interval 34 
COPD  chronic obstructive pulmonary disease  35 
CPB  cardiopulmonary bypass 36 
FEV1   forced expiratory volume in one second 37 
FS  full median sternotomy 38 
HR  hazard ratio 39 
HRQoL health-related quality of life 40 
ICER  incremental cost-effectiveness ratio 41 
LVEF  left ventricular ejection fraction  42 
MS  mini-sternotomy 43 
NHS  National Health Service 44 
OR  odds ratio  45 
QALY  quality-adjusted life year 46 
RCT  randomised control trial  47 
SAE   serious adverse event 48 
SD  standard deviation 49 
TLCO   transfer factor of the lung for carbon monoxide 50 
TOE  transoesophageal echocardiogram 51 
UK  United Kingdom 52 
  53 
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Central Message 54 
 55 
In the UK NHS, compared to conventional median sternotomy approach for surgical AVR, 56 
mini-sternotomy did not hasten recovery or hospital discharge, and was not cost-effective.    57 
 5 
 
Perspective Statement 58 
Minimal access surgery is appealing for its perceived advantages including better patient 59 
recovery, satisfaction and cost-effectiveness.  This RCT conducted within the UK NHS 60 
setting did not demonstrate quicker patient recovery or cost-effectiveness associated with 61 
mini-sternotomy compared to full median sternotomy approach.  These findings are relevant 62 
to physicians, patients and health care funders.  63 
64 
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Structured Abstract 65 
Objective:  Aortic valve replacement (AVR) can be performed either through full median 66 
sternotomy (FS) or upper mini-sternotomy (MS).  The Mini-Stern trial aimed to establish 67 
whether MS leads to quicker postoperative recovery and shorter hospital stay after first-time 68 
isolated AVR.   69 
Methods:   This pragmatic, open-label, parallel RCT compared MS with FS for first-time 70 
isolated AVR in two UK NHS hospitals. Primary endpoints were duration of postoperative 71 
hospital stay and the time to fitness for discharge from hospital after AVR, analysed in the 72 
intent-to-treat population.  73 
Results:  In this RCT, 222 patients were recruited and randomised (118 MS, 104 FS).    74 
Compared to FS patients, MS patients had longer hospital stay (mean 9.5 vs. 8.6 days) and 75 
took longer to achieve fitness for discharge home (mean 8.5 vs. 7.5 days). Adjusting for valve 76 
type, sex and surgeon, hazard ratios (HR) from Cox models did not show a statistically 77 
significant effect of MS (relative to FS) on either hospital stay (HR 0.874, 95% CI 0.668-78 
1.143, p-value 0.3246) or time to fitness for discharge (HR 0.907, 95% CI 0.688-1.197, p-79 
value 0.4914).  During mean follow up of 760 days (MS:745 and FS:777 days), 12 (10%) MS 80 
and 7 (7%) FS patients died (HR 1.871, 95% CI 0.723-4.844, p-value 0.1966). Average extra 81 
cost for MS was £1,714, during the first 12 months after AVR.  82 
Conclusions:  Compared to FS for AVR, MS did not result in shorter hospital stay, faster 83 
recovery or improved survival and was not cost-effective.  MS approach is not superior to FS 84 
for performing AVR. 85 
Word count for Abstract:  248  86 
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Introduction 87 
Aortic valve replacement (AVR) is the second commonest cardiac surgery in the UK [1] with 88 
an increasing proportion of older patients [1, 2].  Minimal access AVR (mAVR) might 89 
shorten hospital stay and postoperative recovery period and could be beneficial if offered 90 
safely and cost-effectively.   91 
 92 
Currently, most AVRs are performed safely through full median sternotomy (FS) [2-6].  93 
However, mAVR may be associated with less postoperative pain, blood loss, pulmonary and 94 
wound complications and shorter hospital stay [2]. The most commonly practised mAVR 95 
involves mini-sternotomy (MS), which could potentially hasten postoperative recovery, 96 
shorten hospital stay and improve patient satisfaction [2-10]. 97 
 98 
Most studies comparing MS and FS for AVR are non-randomised.  Although systematic 99 
reviews with meta-analyses [11, 12] have been conducted, inadequate statistical power and 100 
heterogeneity of studies calls for prospective, randomised control trials (RCTs) to assess 101 
benefits and risks of mAVR.  Published evidence on cost-effectiveness comparing MS to FS 102 
is sparse and weak. A recent review comparing cost-effectiveness of FS and MS called for a 103 
well-designed RCT to evaluate cost-effectiveness of mAVR up to at least a year after surgery 104 
[13]. Recently, a propensity-matched study from the UK national data concluded that mAVR 105 
is safe and was associated with shorter postoperative hospital stay [14]. The authors 106 
concluded that although general clinical equipoise exists between FS and MS, it is essential 107 
to have a well-constructed and adequately powered RCT before widespread adoption of MS.  108 
This retrospective study did not analyse cost-effectiveness of either surgical approach. 109 
 110 
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The Mini-Stern trial assessed whether MS is superior to FS in shortening postoperative 111 
recovery time and improving patient outcomes without compromising patient safety. It also 112 
assessed cost-effectiveness of MS from the perspective of the UK NHS as a health care 113 
provider. 114 
 115 
Materials and Methods 116 
Mini-Stern was a two-centre, pragmatic, open-label RCT conducted in the UK.  Patients were 117 
randomised (1:1) to AVR either by MS or FS.  118 
 119 
 Sample Size 120 
Considering four published RCTs [5, 6, 9, 10] and two cohort studies [7, 8], a 20% reduction 121 
in hospital stay from 11.7 to 9.36 days was considered clinically significant.  Based on an 122 
internal audit of 252 first-time elective AVRs performed at Papworth Hospital in 2007/08 123 
(mean hospital stay 11.7 days, SD 6.2), to detect this change with 80% power and 2-sided 124 
significance of 5%, 110 patients per group were required. As randomisation was performed 125 
on the day of surgery after induction of anaesthesia and introduction of the transoesophageal 126 
echocardiogram (TOE) probe, no subjects dropped out between randomisation and surgery 127 
thereby making the total trial recruitment target, 220 patients. 128 
 129 
Recruitment 130 
Adult patients undergoing first-time isolated AVR were included.  Exclusion criteria included 131 
emergency AVR, LVEF≤ 30%, chest wall deformities, severe COPD (FEV1 or TLCO < 40% 132 
predicted), BMI > 35kg/m2, concomitant cardiac surgery, redo-surgery and inability to 133 
perform TOE. Details of patient enrolment are given in the online protocol. 134 
 135 
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Randomisation 136 
Randomisation (1:1) used random permuted blocks of variable lengths (6 or 8), stratified by 137 
surgeon and valve prosthesis (bio-prosthetic or mechanical). Random allocations were pre-138 
generated, held in secure files by Papworth Trials Unit.  During early days of the trial, TOE 139 
probe could not be passed in four patients due to technical reasons.  These patients underwent 140 
the allocated procedure and were included in the trial. Later the Trial Steering Committee 141 
decided that under such circumstances, MS would be unsafe and patients should be excluded 142 
from the trial to FS.  Since eligibility for MS required TOE, in order to avoid post-143 
randomisation drop-out, group allocation for the study subjects was retrieved via telephone 144 
by theatre staff soon after anaesthesia and introduction of the TOE probe.  Due to the nature 145 
of interventions, this trial could not be blinded.  146 
 147 
Outcomes 148 
Primary endpoints:  Two closely related primary endpoints were measured.  Firstly, length 149 
of postoperative hospital stay (days between surgery and actual hospital discharge) which is 150 
easily measured, a surrogate for early postoperative events and sensitive to outcomes that 151 
affect health-related quality of life (HRQoL).  Secondly, the interval in days between surgery 152 
and the patient being medically fit for discharge. To reduce investigator bias, standard 153 
discharge criteria were followed to decide the day of fitness for discharge. This endpoint was 154 
chosen to address exogenous effects (social factors, lack of transport, non-availability of 155 
space in nursing homes etc.) that commonly delay hospital discharge in the UK. 156 
 157 
Clinical secondary endpoints: duration of surgery,  total theatre time,  aortic cross-clamp 158 
and cardiopulmonary bypass (CPB) times, blood loss in the first 12 hours after surgery,  159 
transfusion of blood and clotting products in the first 48 hours (blood transfusion trigger was 160 
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haemoglobin level < 80g/L),  frequency of re-intubation,  time to initial extubation, 161 
mediastinal drain removal and first independent mobilisation,  daily pain scores at rest and on 162 
deep breath (over the first ten days or until hospital discharge) on a scale of 0 to 10, LVEF 163 
and severity of para-prosthetic regurgitation at hospital discharge and at 6 months, and time 164 
to all-cause death. Definitions of adverse events and details of their reporting are in the online 165 
protocol.  To exclude bias, clinical outcome data were collected by research team  who were 166 
not involved in routine care of subjects, following standardised protocols.   167 
 168 
Non-clinical secondary endpoints:  Health-related Quality of Life and Healthcare resource 169 
use. 170 
HRQoL:  Patients completed EQ-5D-3L [15] and SF-36 [16, 17] questionnaires at baseline, 171 
6 weeks, 6 months and 12 months following surgery. EQ-5D-3L was repeated on fourth 172 
postoperative day and at discharge.   173 
Healthcare resource use:   Patient-specific resource use collected from hospital records and 174 
patient interviews during the primary admission included phases of care including operative 175 
surgery, critical care, post-surgical ward care and medications. Post-discharge resource use 176 
included attending wound clinics, community nurse visits, physiotherapy sessions, 177 
occupational therapy services, medical tests, cost of analgesics and other drugs and further 178 
hospitalisation within the first year after AVR. 179 
 180 
Surgical details 181 
All participating surgeons were consultants experienced in performing AVR by both FS and 182 
MS. They followed the operative surgical protocol as described below. 183 
MS approach: With the patient anaesthetised as per standard protocol, skin was incised from 184 
half-way between the suprasternal notch and the sternal angle to the level of the fourth 185 
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intercostal space, measuring approximately 8cm. The manubrium was divided in the midline 186 
from the suprasternal notch inferiorly and then into the right 4th intercostal space. Thymus 187 
was divided and pericardium opened exposing the ascending aorta, aortic root and right atrial 188 
appendage.  A loading dose of unfractionated heparin 300U/kg followed by boluses of 5000U 189 
was administered to achieve activated clotting time above 450 seconds.  Aorta was 190 
cannulated using a wired flexible aortic cannula. Right atrial appendage was cannulated using 191 
a flat venous cannula and CPB commenced.  The ascending aorta was cross-clamped and 192 
intermittent, antegrade, cold blood cardioplegia administered. The aorta was then incised 193 
open in an oblique or transverse fashion, the diseased valve excised and annulus decalcified.  194 
A suitably sized aortic valve prosthesis was inserted using either horizontal mattress, 2-0 195 
Ethibond sutures or semi-continuous, 2-0 Prolene sutures. Surgeons adopted either of these 196 
suture techniques and adhered to the same technique irrespective of the type of valve 197 
prosthesis or the surgical approach.  Aortotomy was then closed, heart de-aired, right atrial 198 
and ventricular epicardial pacing wires inserted and patient weaned off CPB.  After 199 
confirming satisfactory functioning of the aortic valve prosthesis by TOE, heparin was 200 
reversed with protamine (1mg/100U of heparin).  Chest drains were inserted into the anterior 201 
mediastinum, posterior pericardial space and pleural space if necessary.  Sternal wires were 202 
inserted and incision closed in layers. Conversion to FS was performed to ensure patient 203 
safety if access was difficult or if intraoperative complications occurred.    204 
 205 
FS approach:  Anaesthesia and positioning of patients was the same as for MS approach.  206 
The skin incision was made between the suprasternal notch and the xiphoid process and 207 
sternum divided in the midline from the suprasternal notch to the xiphoid process.  A two-208 
stage venous cannula was used for atrial cannulation.  Remaining steps were similar to MS 209 
approach. 210 
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 Statistical analysis 211 
Analyses of primary and secondary endpoints used intention-to-treat and included all 212 
randomised patients. Unless stated otherwise, statistical models included treatment (MS vs. 213 
FS), valve (mechanical vs. bio-prosthetic) and sex as fixed effects, and surgeons as random 214 
effects. Hypothesis testing was two-sided at the 5% significance level, with no adjustments 215 
for multiple testing. All confidence intervals (CI) were estimated at the 95% confidence level.  216 
Distributions of time-to-event endpoints were compared between study groups using Kaplan-217 
Meier curves and log-rank tests (stratified by sex, valve and surgeon). Hazard ratios (HR) for 218 
MS relative to FS were estimated from a Cox model. The null hypothesis of no treatment 219 
effect (HR = 1) was tested. Patients who were lost to follow-up, withdrew or died before the 220 
event were censored at the latest time they were known to be event-free. Models were 221 
checked by plotting Schoenfeld and deviance residuals.  For primary endpoints, Cox models 222 
were re-fitted using the per-protocol population and in sensitivity analyses (Appendix A. 223 
Table A4).   224 
Need for reintubation and other dichotomous endpoints were compared between groups by 225 
estimating a MS/FS odds ratio (OR) via logistic regression. EQ-5D, SF-36 and pain scores 226 
were modelled using repeated measures linear regression. Where possible, random intercepts 227 
and random time coefficients for patients were included. For EQ-5D and SF-36, fixed effects 228 
for baseline scores were included. Models were fitted using complete cases, then re-fitted 229 
with multiple imputation of missing scores via chained equations.  230 
Serious adverse events (SAEs) were analysed in the safety population according to 231 
intervention received. Patients randomised to MS who crossed over to FS prior to surgery 232 
were considered to have received FS; those who crossed over after MS had commenced were 233 
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considered to have received MS. Rates of SAEs were explored using Poisson regression with 234 
a random patient effect.     235 
 CONSORT guidelines [18] were followed. Analyses were performed in SAS version 9.4 236 
(SAS Institute Inc., Cary, NC, USA). No interim analyses were undertaken but reports were 237 
presented annually to the Data Monitoring and Ethics Committee.  238 
Economic analysis  239 
Unit costs were obtained from nationally published sources in the UK [19, 20, 21, 22] or 240 
from the Finance department, Papworth Hospital when the former did not provide the 241 
required information.  Total cost per patient was calculated by summing resource use items 242 
multiplied by unit costs across the in-patient stay and the 12-month postoperative follow-up 243 
period (Appendix B. Table B7). Health state utilities from the EQ-5D-3L and SF-36, based 244 
on UK value sets [15, 23] were used to generate quality-adjusted life years (QALYs) using 245 
the area under the curve method and assigning a value of zero from date of death.  Missing 246 
values were imputed using chained predictive mean matching, stratified by treatment and 247 
conditional on age, sex and baseline EQ-5D-3L. 248 
  249 
Differences in mean costs and QALYs were estimated using seemingly unrelated regression, 250 
controlling for age, sex, valve, baseline EQ-5D-3L and treatment, to accommodate skewness 251 
[24].  Uncertainty in cost-effectiveness was estimated by drawing 1000 bootstrapped samples 252 
and conducting probabilistic sensitivity analysis. Results are presented as incremental net 253 
monetary benefit at various thresholds of willingness to pay per QALY, cost-effectiveness 254 
planes and cost-effectiveness acceptability curves. Deterministic sensitivity analyses explored 255 
effects of using complete cases only, SF6D-based QALY estimates, the procedure inpatient 256 
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admission only, excluding patients who died and excluding additional equipment costs 257 
(Appendix B. Table B11).  258 
 259 
Results 260 
Overall 1024 patients were screened between 28 January 2010 and 13 April 2015, of whom 261 
222 were recruited and randomised to MS (118) or FS (104).  One-year follow-up was 262 
completed on 23 May 2016.  263 
Study groups were similar at baseline except for a non-significant sex imbalance (Table 1). In 264 
this trial, MS was not completed in 14 (12%) of 118 patients randomised to MS. Of these 265 
patients, 6 (5%) had conversion from MS to FS due to reasons listed in Figure 1. The 266 
remaining 8 patients underwent FS after randomisation to MS but without initial MS incision 267 
as MS was considered unsafe/impractical.  The true rate of intraoperative conversion of MS 268 
to FS was therefore 5%. Four patients (2%, Table 2) were censored before discharge: one 269 
withdrawal before surgery (FS) and three deaths (all randomised to and received MS). A 270 
further thirteen (6%) were censored before fitness for discharge: six discharged to acute 271 
hospital (three MS, three FS), seven to long-term care or rehabilitation (three FS, four MS). 272 
Mean time to hospital discharge was longer for MS than FS (9.5 vs. 8.6 days), as was mean 273 
time to fitness to discharge (8.5 vs. 7.5 days). However, distributions of these endpoints were 274 
similar in both groups (Figure 2, Table 2). The difference was not statistically significant in 275 
either primary analyses using Cox models (Figure 3), log-rank tests (Table 2) or sensitivity 276 
analyses (Appendix A. Table A4). The gamma-distributed frailty term in the Cox models was 277 
estimated to have variance 0.006675 for time to fitness and 0.000100 for time to discharge, 278 
suggesting that surgeon heterogeneity was negligible.  279 
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Time to drain removal (including drains inserted/retained to treat complications) was longer 280 
for MS, but times to extubation and independent mobilisation did not differ significantly 281 
between groups (Table 2, Figure 3), nor did numbers of patients re-intubated (six MS vs. five 282 
FS, OR 1.039, CI 0.306-3.531, p=0.9512). Statistically significant HRs indicated longer 283 
surgery, CPB, cross-clamp and theatre times for MS (Figure 3). No significant differences 284 
were seen in blood loss (Appendix A. Table A3), or in numbers of patients requiring 285 
transfusion of blood (50 MS vs. 51 FS, OR 0.797, CI 0.453-1.402, p=0.4310) or clotting 286 
products (11 MS vs 4 FS, OR 2.616, CI 0.801-8.541, p=0.1112). 287 
Regression models for pain at rest, EQ-5D utilities and SF-36 domain scores (Appendix A. 288 
Tables A6, A7, A8) estimated greater rate of improvement over time in MS patients for three 289 
SF-36 domains (social functioning, vitality and role physical). After multiple imputation, the 290 
difference was only significant for the role physical domain (Appendix A. Table A9). Pain on 291 
deep breath was not analysed as only less than half the data were collected due to poor patient 292 
compliance. 293 
 Nine (4%) patients died within a year of surgery: seven (6%) MS, two (2%) FS.  Five deaths 294 
were possibly related to treatment (four MS, one FS), none were probably or definitely 295 
related (Appendix A. Table A15). Overall, twelve (10%) MS and seven (7%) FS patients died 296 
during follow-up (mean follow-up 760 days: 745 MS, 777 FS).  Time to all-cause death, 297 
adjusted for age, showed a moderately large but statistically non-significant HR (MS/FS) of 298 
1.871 (CI 0.723-4.844, p=0.1966). 299 
Safety analyses excluded one patient who was withdrawn before surgery.  There were 300 
significantly more SAEs in MS recipients (rate ratio 1.615, CI 1.070-2.437, p=0.0225) 301 
(Appendix A. Table A11).  The numbers of patients experiencing SAEs were not 302 
significantly different (OR 1.559, CI 0.895-2.715, p=0.1161). Incidence of para-prosthetic 303 
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regurgitation did not differ significantly between groups (Appendix A. Table A13). Seven 304 
patients developed pericardial collection (three MS vs four FS, OR 0.680, CI 0.146-3.178, 305 
p=0.6229).  Wound infections (including superficial and deep infections) were more common 306 
in FS recipients (thirteen FS vs four MS, OR 0.312, CI 0.097-1.005, p=0.0511). Deep sternal 307 
wound infection developed in one MS and one FS recipient, neither of whom required plastic 308 
surgical repair.     309 
Economic analyses are summarised in Table 4. There was additional cost for MS relative to 310 
FS (£1,714 per patient, p=0.0765) in the first year following surgery. MS patients had (non-311 
significant) better EQ-5D-based QALYs (0.03 per patient, p=0.1509). The incremental cost 312 
per QALY gained was £61,379, but after adjusting for baseline characteristics, MS had 313 
higher costs and lower QALYs (i.e. was dominated).  In deterministic and probabilistic 314 
sensitivity analyses, MS was either dominated or had a very large cost per QALY, except for 315 
the complete case analysis (Appendix B. Tables B11, B12).  316 
Discussion 317 
The UK NHS is a free for patient at point-of-delivery healthcare system. Apart from good 318 
recovery, hospital discharge of a significant proportion of elderly patients depends on the 319 
timely availability of social care services in the community.  The Mini-Stern trial is the first 320 
RCT comparing FS and MS for isolated AVR when performed for UK NHS patients.   321 
 322 
In this prospective, pragmatic, open-label RCT, MS did not reduce the total duration of 323 
hospital stay after AVR.  As hospital discharge is sometimes delayed due to social factors, we 324 
included time until fit for discharge as a second primary endpoint.  This was also not reduced 325 
by MS. These endpoints were recorded by physiotherapists based on a common discharge 326 
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protocol with specific clinical milestones to achieve, thereby excluding physician-induced 327 
bias.  328 
 329 
In this study operation, total theatre, aortic cross-clamp and CPB times were significantly 330 
prolonged with MS. This was expected as in general, minimal access valve operations take 331 
longer [5, 9].  This is justifiable if MS resulted in either faster recovery, shorter postoperative 332 
stay, reduced cost of treatment or more importantly a significant reduction in adverse events 333 
and therefore superior patient safety.  In this RCT, MS did not achieve these benefits and 334 
hence we feel that the prolonged operation time, total theatre, cross-clamp and CPB times are 335 
not justifiable for performing AVR through MS.      336 
 337 
Previously, two meta-analyses [11, 12] concluded that mAVR approaches are superior in 338 
certain aspects of postoperative recovery. However, both included studies on mini-339 
thoracotomy approach for AVR, and therefore inferences drawn cannot be extrapolated to 340 
MS. A retrospective propensity-matched analysis of data from a UK national database 341 
concluded that MS is safe and comparable to conventional AVR [14]. The authors found that 342 
MS resulted in a shorter postoperative hospital stay, which disagrees with our findings.  343 
However, a propensity-matched study can suffer from selection bias if its matching algorithm 344 
produces treatment groups that are unbalanced in some unobserved characteristics.  Recently, 345 
a retrospective study demonstrated safety of right thoracotomy minimally invasive isolated 346 
and concomitant AVR in patients of all age groups [25].  As randomisation balances study 347 
groups in known and unknown characteristics, results of the Mini-Stern trial should be more 348 
reliable than non-randomised studies.   349 
 350 
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Previous studies investigating cost-effectiveness provided unclear answers.  A report 351 
analysing registry data from patients who underwent isolated primary AVR [26] reported 352 
lower hospital cost when AVR was performed through right anterior thoracotomy compared 353 
to sternotomy-based approaches with no significant differences in outcome. The main reasons 354 
attributed to lower costs were earlier hospital discharge and reduced use of blood products. 355 
Ghanta et al [27] noted that exclusion of rehabilitation costs could alter this finding. A review 356 
by Glauber et al [13], based on uncontrolled studies, noted that higher cost of instruments and 357 
devices in mAVR could be offset by economic advantage gained by  shorter hospital stay and 358 
lower complication rates.  The Mini-Stern trial assessed cost-effectiveness using a range of 359 
sensitivity analyses, but only the complete case analysis showed MS to be cost-effective, 360 
suggesting lower costs but slightly worse outcomes with MS.  However, this analysis used a 361 
potentially unrepresentative sample of just 90 patients.   Our analysis was restricted to the 362 
first year following operation without long-term analysis beyond 1 year. 363 
 364 
This RCT is robust with many merits including on-table randomisation, comprehensive and 365 
independent outcome assessment without physician-bias, longer-term clinical assessment, 366 
HRQoL analysis and economic analysis.  However there were some limitations. Although we 367 
report on secondary endpoints, this trial was powered only to address the primary endpoint.  368 
A total of 14 patients (12%) allocated to MS received FS, which could be another limitation.  369 
However, only 6 patients (5%) had true conversion after an attempted MS, while 8 patients 370 
(6.7%) went on to FS for safety reasons.  Although this RCT took place in only two centres, 371 
thereby limiting generalisability, recruitment by eight surgeons improves generalisability.  A 372 
total of 1024 patients were screened to recruit 222 (21.7%) patients.  Although this 373 
potentially suggests selection bias, only 125 eligible patients (12.2%) failed recruitment while 374 
the remaining 667 patients (65.1%) did not meet inclusion criteria.  Blinding was not 375 
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practical as sternotomy dressings were usually changed 48 hours after surgery and patients 376 
became aware of the approach.  This could have caused bias in self-reported outcomes. 377 
Missing ‘pain at rest’ data were unlikely to be missing at random, and therefore imputation 378 
might not have addressed all potential biases. Despite having two primary outcomes, we did 379 
not adjust for multiple testing.  However, as neither showed a significant difference between 380 
groups, this would not have affected our conclusions.   381 
 382 
In conclusion, MS for AVR did not result in quicker recovery or earlier hospital discharge.  383 
MS resulted in longer operations, increased costs, and resulted in more SAEs than FS. 384 
Overall, this pragmatic RCT did not provide evidence that MS results in better clinical or 385 
quality of life outcomes, or that MS is cost-effective compared to FS in the first year after 386 
AVR.  387 
 388 
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Legends 401 
Central Picture Legend:  Duration of hospital stay after AVR: FS versus MS. 402 
Video Legend: MS approach for AVR. 403 
Figure 1. Trial flow diagram.  404 
Figure 2. Kaplan-Meier curves for primary endpoints. Points indicate censoring and dashed 405 
lines represent 95% confidence intervals.  406 
Figure 3. Forest plot of HRs and 95% confidence intervals from Cox models.  407 
 Figure 4. Cost-effectiveness planes. Proportion of points below each threshold gives the 408 
probability that MS is more cost-effective than FS. This probability is 3.7% for willingness to 409 
pay £20,000/QALY and 5.1% for willingness to pay £30,000/QALY. 410 
 411 
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Table 1.   Baseline characteristics 412 
 MS (n = 118) FS (n = 104) 
Age (years) - Mean (SD) 71.3 (12.3) 72.1 (10.9) 
BMI (kg/m2) – Mean (SD) 26.6 (3.2) 27.7 (3.7) 
Sex - frequency (%)   
Female 53 (45%) 57 (55%) 
Male 65 (55%) 47 (45%) 
Valve type - frequency (%)   
Mechanical 15 (13%) 14 (13%) 
Tissue 103 (87%) 90 (87%) 
EuroSCORE (%) - Mean (SD) 5.9 (2.1) * 6.1 (2.1) 
* EuroSCORE was missing for one MS patient. 413 
 414 
 415 
 416 
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Table 2. Kaplan-Meier medians (quartiles) for time-to-event endpoints 417 
 MS (n = 118) FS (n = 104) p-value* 
Time to discharge (days) 7 (6, 10) 7 (6, 10)  0.6924 
Censored 3 1  
Time until fit for discharge (days) 6 (5, 10) 6 (5, 9) 0.5597 
Censored 10 7  
Time to independent mobilisation (days) 4 (3, 7) 4 (3, 6)  0.5819 
Censored 8 7  
Time to mediastinal drain removal (hours) 26.1 (20.6, 53.3) 22.5 (19.4, 37.8)  0.0157 
Censored 2 2  
Time to extubation (hours) 9.2 (7.8, 12.1) 8.3 (6.8, 11.7)  0.5488 
Censored 1 1  
Theatre time (minutes) 191 (172, 225) 176 (152, 203) < 0.0001 
Censored 0 0  
CPB time (minutes) 80 (70, 95) 66 (52, 85)  < 0.0001 
Censored 0 0  
Cross-clamp time (minutes) 65 (53, 76) 49 (39, 64)  < 0.0001 
Censored 0 0  
Surgery duration (minutes) 163 (139, 190) 149 (114, 167)  < 0.0001 
Censored 3 4  
*Log-rank test. Seven surgery durations were not recorded and censored at 1 minute.  418 
  419 
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Table 3. Costs, QALYs and Cost-effectiveness 420 
 Cost and QALYs  
(with imputation)  
 
FS (n = 118) MS (n = 104) 
Mean Cost 
per patient 
SD Mean Cost 
per patient 
SD 
Primary Admission 
Costs 
Theatre use £3,824 £1,243 £4,422 £2,053 
Additional surgical items £16.52 £0.0 £52.0 £0.0 
Critical care (ITU) £1,834 £3,023 £2,934 £5,030 
Cardiac ward £2,744 £1,664 £2,676 £1,500 
Physio- and Occupational Therapy £77 £55 £78 £68 
Rehabilitation £384 £1,878 £263 £1,621 
Acute hospital £347 £1,919 £298 £1,971 
Sub-total cost £9,226 £6,511 £10,724 £8,850 
Post primary 
admission costs to 
12 months 
Hospital Re-admission £418 £1,475 £575 £1,863 
Follow up tests £224 £258 £282 £279 
Follow up healthcare visits £373 £359 £311 £263 
           Sub-total cost £1,015 £1,778 £1,168 £2,079 
 
Drugs 
 
£379 
 
£548 
 
£441 
 
£977 
Total cost over 12 months £10,620 £7,624 £12,333 £9,864 
Incremental cost- 
effectiveness*  
(probabilistic 
analysis with 
Incremental cost at 12 months (MS-FS) £2,154.0 (SE £36) 
Incremental EQ-5D-3L QALYs (MS-FS) -0.0122 (SE 0.0008) 
ICER MS dominated by FS 
NMB (at WTP £20,000/QALY) -£2,397 
NMB (at WTP £30,000/QALY) -£2,519 
 24 
 
baseline 
adjustment) 
SD: standard deviation, SE: standard error, WTP: willingness to pay, NMB: net monetary benefit, ICER: incremental 
cost-effectiveness ratio.  * Incremental costs and effects estimated using SUR, adjusting for baseline differences. 
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Glossary of Abbreviations 37 
 38 
AVR  aortic valve replacement  39 
mAVR  minimal access aortic valve replacement 40 
BMI  body mass index 41 
CI  95% confidence interval 42 
COPD  chronic obstructive pulmonary disease  43 
CPB  cardiopulmonary bypass 44 
FEV1   forced expiratory volume in one second 45 
FS  full median sternotomy 46 
HR  hazard ratio 47 
HRQoL health-related quality of life 48 
ICER  incremental cost-effectiveness ratio 49 
LVEF  left ventricular ejection fraction  50 
MS  mini-sternotomy 51 
NHS  National Health Service 52 
OR  odds ratio  53 
QALY  quality-adjusted life year 54 
RCT  randomised control trial  55 
SAE   serious adverse event 56 
SD  standard deviation 57 
TLCO   transfer factor of the lung for carbon monoxide 58 
TOE  transoesophageal echocardiogram 59 
UK  United Kingdom 60 
  61 
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Central Message 62 
 63 
In the UK NHS, compared to conventional median sternotomy approach for surgical AVR, 64 
mini-sternotomy did not hasten recovery or hospital discharge, and was not cost-effective.    65 
 5 
 
Perspective Statement 66 
Minimal access surgery is appealing for its perceived advantages including better patient 67 
recovery, satisfaction and cost-effectiveness.  This RCT conducted within the UK NHS 68 
setting did not demonstrate quicker patient recovery or cost-effectiveness associated with 69 
mini-sternotomy compared to full median sternotomy approach.  These findings are relevant 70 
to physicians, patients and health care funders.  71 
72 
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Structured Abstract 73 
Objective:  Aortic valve replacement (AVR) can be performed either through full median 74 
sternotomy (FS) or upper mini-sternotomy (MS).  The Mini-Stern trial aimed to establish 75 
whether MS leads to quicker postoperative recovery and shorter postoperative hospital stay 76 
after first-time isolated AVR.   77 
Methods:   This pragmatic, open-label, parallel RCT compared MS with FS for first-time 78 
isolated AVR patients in two UK NHS hospitals. Primary endpoints were duration of 79 
postoperative hospital stay and the time to fitness for discharge from hospital after AVR, 80 
analysed in the intent-to-treat population.  81 
Results:  In this RCT, 222 patients were recruited and randomised (118 MS, 104 FS).    82 
Compared to FS patients, MS patients had longer hospital stay (mean 9.5 vs. 8.6 days) and 83 
took longer to achieve fitness for discharge home (mean 8.5 vs. 7.5 days). Adjusting for valve 84 
type, sex and surgeon, hazard ratios (HR) from Cox models did not show a statistically 85 
significant effect of MS (relative to FS) on either hospital stay (HR 0.874, 95% CI 0.668-86 
1.143, p-value 0.3246) or time to fitness for discharge home (HR 0.907, 95% CI 0.688-1.197, 87 
p-value 0.4914).  During mean follow up of 760 days (MS:745 and FS:777 days), follow-up, 88 
12 (10%) MS and 7 (7%) FS patients died (HR 1.871, 95% CI 0.723-4.844, p-value 0.1966). 89 
Average extra cost for MS was £1,714, patients had higher cost of treatment during the first 90 
12 months after AVR.  91 
Conclusions:  Compared to FS approach for for AVR, MS did not result in shorter hospital 92 
stay, faster recovery or improved survival and was not cost-effective.  MS approach is not 93 
superior to FS for performing AVR. 94 
Word count for Abstract:  242248  95 
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Introduction 96 
Aortic valve replacement (AVR) is the second commonest adult cardiac surgery in the UK 97 
[1] with an increasing proportion of older patients [1, 2].  Minimal access AVR (mAVR) 98 
might shorten hospital stay and , postoperative recovery period and could be beneficial if 99 
offered cost-effectively without compromising safetyquality of care.     100 
 101 
Currently, most AVRs are performed safely throughvia full median sternotomy (FS) [2-6].   102 
which allows safe conduct of the operation.  The disadvantages include a longer incision and 103 
full-length sternotomy, which might prolong recovery.  However, Although results vary 104 
among centres, mAVRinimally invasive approach may be is associated with less 105 
postoperative pain, blood loss, pulmonary and wound complications and shorter hospital stay 106 
[2]. The most commonly practised mAVR involves mini-sternotomy (MS) incision, which 107 
could potentially hasten postoperative recovery, shorten reducing hospital stay and 108 
improveing patient satisfaction [2-10].  109 
 110 
Most The majority of studies publications comparing MS and FS for AVR arerepresent non-111 
randomised.   studies. Although systematic reviews with meta-analyses [11, 12] have been 112 
conducted, inadequate statistical power and heterogeneity of studies calls forreinforced the 113 
need for prospective, randomised control trials (RCTs) to assess benefits and risks of mAVR.  114 
Published evidence on cost-effectiveness comparing  of MS compared to FS approach is also 115 
sparse and weak. A recent review comparing cost-effectiveness of FS and MS called for a 116 
well-designed RCT to evaluate cost-effectiveness of mAVR up to at least a year after surgery 117 
[13]. Recently a propensity-matched study from the UK national data concluded that mAVR 118 
is safe and was associated with a shorter postoperative hospital stay [14]. The authors 119 
concluded that although general there is general clinical equipoise exists between FS and MS 120 
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approach, it is essential to have a well-constructed and adequately powered prospective RCT 121 
before widespread adoption of MS. approach. This retrospective study did not analyse cost-122 
effectiveness of either surgical approach. 123 
 124 
The Mini-Stern trial assessed was designed to assess whether MS is superior to FS in 125 
shortening postoperative recovery time and improving patient outcomes without 126 
compromising patient safety. It also assessed cost-effectiveness of MS approach from the 127 
perspective of the UK NHS as a health care provider. 128 
 129 
Materials and Methods 130 
 131 
 132 
Mini-Stern was a two-centre, pragmatic, open-label RCT conducted in the UK.  Patients were 133 
randomised (1:1) to AVR either by a MS or FS approach.  134 
 135 
 136 
 Sample Size 137 
Considering four published RCTs [5, 6, 9, 10] and two cohort studies [7, 8], a 20% reduction 138 
in hospital stay from 11.7 to 9.36 days was considered clinically significant.  Based on an 139 
internal audit of 252 first-time elective AVRs performed at Papworth Hospital in 2007/08 140 
(mean hospital stay 11.7 days, SDstandard deviation 6.2), to detect this change with 80% 141 
power and a 2-sided significance of 5%, 110 patients per group were required. As 142 
randomisation was performed on the day of surgery after induction of anaesthesia and 143 
introduction of the transoesophageal echocardiogram (TOE) probe, no subjects dropped out 144 
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between randomisation and surgery thereby making the total trial recruitment target, 220 145 
patients. 146 
 147 
 148 
 149 
 150 
 151 
Recruitment 152 
Adult patients undergoing first-time isolated AVR were included.  Exclusion criteria included 153 
emergency AVRoperations, LVEF≤ 30%, chest wall deformities, severe emphysema or 154 
COPD (FEV1 or TLCO < 40% predicted), BMI > 35kg/m2, concomitant cardiac surgery, 155 
redo-surgery and inability to perform TOE. Details of patient enrolment are given in the 156 
online protocol. 157 
 158 
Randomisation 159 
Randomisation (1:1) used random permuted blocks of variable lengths (6 or 8), stratified by 160 
surgeon and valve prosthesis (bio-prosthetic or mechanical). Random allocations were pre-161 
generated, held in secure files by Papworth Trials Unit.  During early days of the trial, TOE 162 
probe could not be passed in four patients due to technical reasons.  These patients underwent 163 
the allocated procedure and were included in the trial. Later the Trial Steering Committee 164 
decided that under such circumstances, MS would be unsafe and patients should be excluded 165 
from the trial to FS.  Since eligibility for MS required a TOE, in order to avoid post-166 
randomisation drop-out, group allocation for the study subjects was retrieved via telephone 167 
by theatre staff soon after anaesthesia and introduction of the TOE probe.  Due to the nature 168 
of the interventions, thise trial could not be blinded.  169 
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 170 
Outcomes 171 
Primary endpoints:  Two closely related primary endpoints were measured.  Firstly, length 172 
of postoperative hospital stay (days between surgery and actual hospital discharge) which is 173 
easily measured, a surrogate for early postoperative events and sensitive to outcomes that 174 
affect health-related quality of life (HRQoL).  Secondly, the interval in days between surgery 175 
and the patient being considered medically fit for discharge. To In order to reduce 176 
investigator bias, standard discharge criteria were followed to decide the day of fitness for 177 
discharge. This endpoint was chosen to address exogenous effects (social factors, lack of 178 
transport, non-availability of space in nursing homes etc.) that commonly delay hospital 179 
discharge of patients in the UK. 180 
Clinical secondary endpoints: duration of surgery,  total theatre time,  aortic cross-clamp 181 
and cardiopulmonary bypass (CPB) times, blood loss in the first 12 hours after surgery,  182 
transfusion of blood and clotting products in the first 48 hours (blood transfusion trigger was 183 
haemoglobin level < 80g/L),  frequency of re-intubation,  time to initial extubation, 184 
mediastinal drain removal and first independent mobilisation (walking unassisted or with 185 
mobility aid if required),  daily pain scores at rest and on deep breath (over the first ten days 186 
or until hospital discharge) on a scale of 0 to 10, LVEF and severity of para-prosthetic 187 
regurgitation  (assessed by echocardiography at hospital discharge and at 6 months), and time 188 
to all-cause death. Definitions of adverse events and details of their reporting are given in the 189 
online protocol.  ToIn order to  exclude bias, clinical outcome data were collected by research 190 
team staff who were not involved in routine care of trial subjects, following standardised 191 
protocols.   192 
 193 
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Non-clinical secondary endpoints:  Health-related Quality of Life and Healthcare resource 194 
use. 195 
HRQoL:  Patients completed EQ-5D-3L [15] and SF-36 [16, 17] questionnaires at baseline, 196 
6 weeks, 6 months and 12 months following surgery. EQ-5D-3L was also repeated onat 197 
fourth postoperative day 4 and at discharge.   198 
Healthcare resource use:   Patient-specific resource use collected from hospital records and 199 
patient interviews during the primary admission included various phases of care including 200 
operative surgery, post-surgical critical care, care in the post-surgical ward care-care and 201 
medications. Post-discharge resource use included attending wound clinics, 202 
community/district nurse visits, physiotherapy sessions, use of occupational therapy services, 203 
medical tests, cost of use of analgesicsa and other  drugs  and other pharmaceutical expenses, 204 
and further hospitalisation  admissions within the first year after AVR. 205 
 206 
Surgical details 207 
All participating cardiac surgeons were consultants experienced in performing AVR by both 208 
FS and MS. They All participating surgeons agreed on and followed adhered to the operative 209 
surgical protocol as described below. 210 
MS approach: With the patient anaesthetised as per standard protocol, skin was incised from 211 
half-way between the suprasternal notch and the sternal angle to the level of the fourth 212 
intercostal space, measuring approximately 8cm. The manubrium was divided in the midline 213 
from the suprasternal notch inferiorly and then into the right 4th intercostal space. Thymus 214 
was divided in the midline and pericardium opened exposing the ascending aorta, aortic root 215 
and right atrial appendage.  A loading dose of unfractionated hHeparin 300U/kg followed by 216 
boluses of 5000U was administered to achieve activated clotting time above 450 seconds.  217 
Aorta was cannulated using a wired flexible aortic cannula. Right atrial appendage was 218 
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cannulated using a flat venous cannula and CPB commenced.  The ascending aorta was 219 
cross-clamped and intermittent, antegrade, cold blood cardioplegia administered. The aorta 220 
was then incised open in an oblique or transverse fashion, the diseased valve excised and 221 
annulus decalcified.  A suitably sized aortic valve prosthesis was inserted using either 222 
horizontal mattress, 2-0 Ethibond sutures or semi-continuous, 2-0 Prolene sutures. Surgeons 223 
adopted either of these suture techniques and adhered to the same technique irrespective of 224 
the type of valve prosthesis or the surgical approach.  Aortotomy was then closed, heart de-225 
aired, right atrial and ventricular epicardial pacing wires inserted and patient weaned off 226 
CPB.  After confirming satisfactory functioning of the aortic valve prosthesis by TOE, 227 
heparin was reversed with protamine (1mg/100U of hHeparin).  Chest drains were inserted 228 
into the anterior mediastinum, posterior pericardial space and pleural space if necessary.  229 
Sternal wires were inserted and incision closed in layers. Conversion to FS was performed to 230 
ensure patient safety if access was difficult or if intraoperative complications occurred.     231 
FS approach:  Anaesthesia and positioning of patients was the same as for MS approach.  232 
The skin incision was made between the suprasternal notch and the xiphoid process and 233 
sternum divided in the midline from the suprasternal notch to the xiphoid process.  A two-234 
stage venous cannula was used for atrial cannulation.  Remaining steps were similar to MS 235 
approach. 236 
 237 
 Statistical analysis 238 
Analyses of primary and secondary endpoints used intention-to-treat and included all 239 
randomised patients. Unless stated otherwise, statistical models included treatment (MS vs. 240 
FS), valve (mechanical vs. bio-prosthetic) and sex as fixed effects, and surgeons as random 241 
effects. Hypothesis testing was two-sided at the 5% significance level, with no adjustments 242 
for multiple testing. All confidence intervals (CI) were estimated at the 95% confidence level.  243 
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Distributions of time-to-event endpoints were compared between study groups using Kaplan-244 
Meier curves and log-rank tests (stratified by sex, valve and surgeon). Hazard ratios (HR) for 245 
MS relative to FS were estimated from a Cox model. The null hypothesis of no treatment 246 
effect (HR = 1) was tested. Patients who were lost to follow-up, withdrew or died before the 247 
event were censored at the latest time they were known to be event-free. Models were 248 
checked by plotting Schoenfeld and deviance residuals.  For primary endpoints, Cox models 249 
were re-fitted using the per-protocol population and in sensitivity analyses (Appendix A. 250 
Table A4).   251 
Need for reintubation and other dichotomous endpoints were compared between groups by 252 
estimating a MS/FS odds ratio (OR) via logistic regression. EQ-5D, SF-36 and pain scores 253 
were modelled using repeated measures linear regression. Where possible, random intercepts 254 
and random time coefficients for patients were included. For EQ-5D and SF-36, fixed effects 255 
for baseline scores were included. Models were fitted using complete cases, then re-fitted 256 
with multiple imputation of missing scores via chained equations.  257 
Serious adverse events (SAEs) were analysed in the safety population according to 258 
intervention received. Patients randomised to MS who crossed over to FS prior to surgery 259 
were considered to have received FS; those who crossed over after MS had commenced were 260 
considered to have received MS. Rates of SAEs were explored using Poisson regression with 261 
a random patient effect.     262 
 CONSORT guidelines [18] were followed. Analyses were performed in SAS version 9.4 263 
(SAS Institute Inc., Cary, NC, USA). No interim analyses were undertaken but reports were 264 
presented annually to the Data Monitoring and Ethics Committee.  265 
Economic analysis  266 
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Unit costs were obtained from nationally published sources in the UK [19, 20, 21, 22] or 267 
from the Finance department, Papworth Hospital when the former did not provide the 268 
required information.  Total cost per patient was calculated by summing resource use items 269 
multiplied by unit costs across the in-patient stay and the 12-month postoperative follow-up 270 
period (Appendix B. Table B7). Health state utilities from the EQ-5D-3L and SF-36, based 271 
on UK value sets [15, 23] were used to generate quality-adjusted life years (QALYs) using 272 
the area under the curve method and assigning a value of zero from date of death.  Missing 273 
values were imputed using chained predictive mean matching, stratified by treatment and 274 
conditional on age, sex and baseline EQ-5D-3L. 275 
  276 
Differences in mean costs and QALYs were estimated using seemingly unrelated regression, 277 
controlling for age, sex, valve, baseline EQ-5D-3L and treatment, to accommodate skewness 278 
[24].  Uncertainty in cost-effectiveness was estimated by drawing 1000 bootstrapped samples 279 
and conducting probabilistic sensitivity analysis. Results are presented as incremental net 280 
monetary benefit at various thresholds of willingness to pay per QALY, cost-effectiveness 281 
planes and cost-effectiveness acceptability curves. Deterministic sensitivity analyses explored 282 
effects of using complete cases only, SF6D-based QALY estimates, the procedure inpatient 283 
admission only, excluding patients who died and excluding additional equipment costs 284 
(Appendix B. Table B11).  285 
 286 
Results 287 
Overall 1024 patients were screened between two NHS hospitals in the UK between 28 288 
January 2010 and 13 April 2015, of whom 222 were recruited and randomised to MS (118) or 289 
FS (104).  One-year follow-up was completed on 23 May 2016.  290 
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Study groups were similar at baseline except for a non-significant sex imbalance (Table 1). In 291 
this trial, MS approach was not completed in 14 (12%) of 118 patients randomised to MS. Of 292 
these patients, 6 (5%) had conversion from MS to FS due to reasons listed in Figure 1. The 293 
remaining 8 patients underwent FS after randomisation to MS but without initial MS incision 294 
as MS approach was considered unsafe / impractical.   in this pragmatic trial.  The true rate of 295 
intraoperative conversion of MS to FS was therefore 5%. Four patients (2%, Table 2) were 296 
censored before discharge: one withdrawal before surgery (FS) and three deaths (all 297 
randomised to and received MS). A further thirteen (6%) were censored before fitness for 298 
discharge: six discharged to acute hospital (three MS, three FS), seven to long-term care or 299 
rehabilitation (three FS, four MS). 300 
Mean time to actual hospital discharge was longer for MS than FS (9.5 vs. 8.6 days), as was 301 
mean time to achieve fitness to discharge (8.5 vs. 7.5 days). However, distributions of these 302 
endpoints were similar in both groups (Figure 2, Table 2). The difference was not statistically 303 
significant in either primary analyses using Cox models (Figure 3), log-rank tests (Table 2) or 304 
sensitivity analyses (Appendix A. Table A4). The gamma-distributed frailty term in the Cox 305 
models was estimated to have variance 0.006675 for time to fitness and 0.000100 for time to 306 
discharge, suggesting that surgeon heterogeneity was negligible.  307 
Time to drain removal (including drains inserted/retained to treat complications) was longer 308 
for MS, but times to extubation and independent mobilisation did not differ significantly 309 
between groups (Table 2, Figure 3), nor did numbers of patients re-intubated (six MS vs. five 310 
FS, OR 1.039, CI 0.306-3.531, p=0.9512). Statistically significant HRs indicated longer 311 
surgery, CPB, cross-clamp and theatre times for MS (Figure 3). No significant differences 312 
were seen in blood loss (Appendix A. Table A3), or in numbers of patients requiring 313 
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transfusion of blood (50 MS vs. 51 FS, OR 0.797, CI 0.453-1.402, p=0.4310) or clotting 314 
products (11 MS vs 4 FS, OR 2.616, CI 0.801-8.541, p=0.1112). 315 
Regression models for pain at rest, EQ-5D utilities and SF-36 domain scores (Appendix A. 316 
Tables A6, A7, A8, A9) estimated greater rate of improvement over time in MS patients for 317 
three SF-36 domains (social functioning, vitality and role physical). After multiple 318 
imputation, the difference was only significant for the role physical domain (Appendix A. 319 
Table A9). Pain on deep breath was not analysed as only less than half the data were 320 
collected due to poor patient compliance. 321 
 Nine (4%) patients died within a year of surgery: seven (6%) MS,  and two (2%) FS.  Five 322 
deaths were possibly related to treatment (four MS, one FS), none were probably or definitely 323 
related (Appendix A. Table A15).. Overall, twelve (10%) MS and seven (7%) FS patients 324 
died during follow-up (mean follow-up 760 days: 745 MS, 777 FS).  Time . In Cox models, 325 
time to all-cause death, adjusted for age, showed a moderately large but statistically non-326 
significant HR (MS/FS) of 1.871 (CI 0.723-4.844, p=0.1966). 327 
Safety analyses excluded one patient who was withdrawn before surgery.  There were 328 
significantly more SAEs in MS recipients (rate ratio 1.615, CI 1.070-2.437, p=0.0225) 329 
(Appendix A. Table A11).   The numbers of patients experiencing SAEs were not 330 
significantly different (OR 1.559, CI 0.895-2.715, p=0.1161). Incidence of para-prosthetic 331 
regurgitation did not differ significantly between groups (Appendix A. Table A13). Seven 332 
patients developed pericardial collection (three MS vs four FS, OR 0.680, CI 0.146-3.178, 333 
p=0.6229).  Wound infections (including superficial and deep infections) were more common 334 
in FS recipients (thirteen FS vs four MS, OR 0.312, CI 0.097-1.005, p=0.0511). Deep sternal 335 
wound infection developed in one MS and one FS recipient, neither of whom required plastic 336 
surgical repair.     337 
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Economic analyses are summarised in Table 4. There was additional cost for MS relative to 338 
FS (£1,714 per patient, p=0.0765) in the first year following surgery. MS patients had (non-339 
significant) better EQ-5D-based QALYs (0.03 per patient, p=0.1509). The incremental cost 340 
per QALY gained was £61,379, but after adjusting for baseline characteristics, MS had 341 
higher costs and lower QALYs (i.e. was dominated).  In deterministic and probabilistic 342 
sensitivity analyses, MS was either dominated or had a very large cost per QALY, except for 343 
the complete case analysis (Appendix B. Tables B11, B12).  344 
Discussion 345 
The UK NHS is a free for patient at point-of-delivery healthcare system. Apart from good 346 
recovery, hospital discharge of a significant proportion of elderly patients depends on the 347 
timely availability of social care services in the community.  for a significant proportion of 348 
elderly patients, hospital discharge depends on the timely availability of social care services 349 
in the community.  The Mini-Stern trial is the first RCT comparing the effect of FS and MS 350 
approaches for isolated AVR when performed for UK NHS patients.   351 
 352 
In this prospective, pragmatic, open-label RCT, MS approach did not reduce the total 353 
duration of hospital stay after AVR.  As hospital discharge is sometimes delayed due to social 354 
factors, we included time until fit for hospital discharge as a second primary endpoint.  This 355 
was also not reduced by MS approach. These primary endpoints were recorded by 356 
physiotherapists based on a common discharge protocol with specific clinical milestones to 357 
achieve, thereby excluding which excluded physician-induced bias.  358 
 359 
In this study we have demonstrated that MS approach recorded significantly greater 360 
operation, total theatre, aortic cross-clamp and CPB times were significantly prolonged with 361 
MS. This was expected as in general, minimal access valve operations take longer [5, 9]. 362 
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compared to conventional approach. This is e prolonged operation time, total theatre, cross-363 
clamp and CPB times associated with MS approach is justifiable if MS it resulted in either 364 
faster recovery, shorter postoperative stay, reduced cost of treatment or more importantly a 365 
significant reduction in adverse events and therefore superior patient safety.  In this RCT, MS 366 
did not achieve these benefits and hence we feel that the prolonged operation time, total 367 
theatre, cross-clamp and CPB times are not justifiable for performing AVR through a MS. 368 
approach.      369 
 370 
Previously, two meta-analyses [11, 12] concluded that mAVR approaches are superior in 371 
certainsome aspects of postoperative recovery. However, both included studies on mini-372 
thoracotomy approach for AVR, and therefore inferences drawn cannot be extrapolated to 373 
MS. Recently aA retrospective propensity- matched analysis of data from a UK national 374 
database concluded that MS mini-sternotomy approach for AVR is safe and comparable to 375 
conventional AVR [14]. The authors found that thatMSmini-sternotomy approach  resulted in 376 
a shorter postoperative hospital stay, which disagrees with our findings.  However, a 377 
propensity-matched study can suffer from selection bias if its matching algorithm produces 378 
treatment groups that are unbalanced in some unobserved characteristics.  Recently, a 379 
retrospective study demonstrated safety of right thoracotomy minimally invasive isolated and 380 
concomitant AVR in patients of all age groups [25].  As rRandomisation balances study 381 
groups in known and unknown characteristics, therefore results of the results of the Mini-382 
Stern Mini-Stern trial  should be more reliable than non-randomised studies.  .  The authors of 383 
this study concluded that a well-conducted and adequately powered prospective RCT is 384 
essential before wider adoption of MS approach for AVR.   385 
 386 
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Previous studies investigating cost-effectiveness provided unclear answers.  A report 387 
analysing registry data from patients who underwent isolated primary AVR [265] reported 388 
lower hospital cost when AVR was performed through right anterior thoracotomy compared 389 
to sternotomy-based approaches with no significant differences in outcome. The main reasons 390 
attributed to lower costs were earlier hospital discharge and reduced use of blood products. 391 
Ghanta et al [276] noted that exclusion of rehabilitation costs could alter this finding. A 392 
review by Glauber et al [13], based on uncontrolled studies, noted that higher cost of 393 
instruments and devices in mAVR could be offset by economic advantage gained by  shorter 394 
hospital stay and lower complication rates.  The Mini-Stern trial Mini-Stern trial  assessed 395 
cost-effectiveness using a range of sensitivity analyses, but only the complete case analysis 396 
showed MS to be cost-effective, suggesting lower costs but slightly worse outcomes with in 397 
MS.   patients. However, this analysis used a potentially unrepresentative sample of just 90 398 
patients.   Our analysis was restricted to the first year following operation without long-term 399 
analysis beyond 1 year. 400 
 401 
  402 
 403 
This RCT is robust with many meritsstrengths  including on-table randomisation, 404 
comprehensive and independent outcome assessment without physician/researcher-bias, and 405 
longer-term clinical assessment, HRQoL analysis and economic analysis.   than previous 406 
studies.  However there were some limitations. Although we report on secondary endpoints, 407 
this trial was powered only to address the primary endpoint.  .  A total of 14 patients (12%) 408 
allocated to MS received FS, which could be another limitation.  However, only 6 patients 409 
(5%) had true conversion after an attempted MS, while 8 patients (6.7%) went on to FS for 410 
safety reasons.  Although this This RCT took place in only two centres, thereby limiting 411 
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generalisability, recruitment by eight surgeons improves generalisability.  .  However, in total 412 
eight surgeons recruited patients into the trial which improved generalisability.  A total of 413 
1024 patients were screened to recruit 222 (21.7%) patients.  Although this potentially 414 
suggests selection bias, only 125 eligible patients (12.2%) failed recruitment while the 415 
remaining 667 patients (65.1%) did not meet inclusion criteria.  Blinding Blinding was not 416 
practical as sternotomy dressings were usually changed 48 hours after surgery and patients 417 
would becaome aware of the surgical approach.  This could have caused bias in self-reported 418 
outcomes. Missing ‘pain at rest’ data were unlikely to be missing at random, and therefore 419 
imputation might not have addressed all potential biases. Despite having two primary 420 
outcomes, we did not adjust for multiple testing.  However, as neither showed a significant 421 
difference between groups, this would not have affected our conclusions.   422 
 423 
In conclusion, MS for AVR did not result in quicker recovery or earlier hospital discharge.  424 
MS resulted in quired longer operations, duration of surgical procedures and increased costs, 425 
and resulted in more SAEs than FS. Overall, this pragmatic RCT did not provide evidence 426 
that MS results in better clinical or quality of life outcomes, or that MS is cost-effective, 427 
when  compared to FS in the first year after AVR.  428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
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 468 
Legends 469 
Central Picture Legend:  Duration of hospital stay after AVR: FS versus MS. 470 
 471 
Video Legend: MS approach for AVR. 472 
 473 
Figure 1. Trial flow diagram.  474 
 475 
Figure 2. Kaplan-Meier curves for primary endpoints. Points indicate censoring and dashed 476 
lines represent 95% confidence intervals.  477 
 478 
Figure 3. Forest plot of HRs and 95% confidence intervals from Cox models.  479 
  480 
Figure 4. Cost-effectiveness planes. Proportion of points below each threshold gives the 481 
probability that MS is more cost-effective than FS. This probability is 3.7% for willingness to 482 
pay £20,000/QALY and 5.1% for willingness to pay £30,000/QALY. 483 
 484 
 485 
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Table 1.   Baseline characteristics 486 
 MS (n = 118) FS (n = 104) 
Age (years) - Mean (SD) 71.3 (12.3) 72.1 (10.9) 
BMI (kg/m2) – Mean (SD) 26.6 (3.2) 27.7 (3.7) 
Sex - frequency (%)   
Female 53 (45%) 57 (55%) 
Male 65 (55%) 47 (45%) 
Valve type - frequency (%)   
Mechanical 15 (13%) 14 (13%) 
Tissue 103 (87%) 90 (87%) 
EuroSCORE (%) - Mean (SD) 5.9 (2.1) * 6.1 (2.1) 
* EuroSCORE was missing for one MS patient. 487 
 488 
 489 
 490 
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Table 2. Kaplan-Meier medians (quartiles) for time-to-event endpoints 491 
 MS (n = 118) FS (n = 104) p-value* 
Time to discharge (days) 7 (6, 10) 7 (6, 10)  0.6924 
Censored 3 1  
Time until fit for discharge (days) 6 (5, 10) 6 (5, 9) 0.5597 
Censored 10 7  
Time to independentfirst mobilisation 
(days) 
4 (3, 7) 4 (3, 6)  0.5819 
Censored 8 7  
Time to mediastinal drain removal (hours) 26.1 (20.6, 53.3) 22.5 (19.4, 37.8)  0.0157 
Censored 2 2  
Time to extubation (hours) 9.2 (7.8, 12.1) 8.3 (6.8, 11.7)  0.5488 
Censored 1 1  
Theatre time (minutes) 191 (172, 225) 176 (152, 203) < 0.0001 
Censored 0 0  
CPB time (minutes) 80 (70, 95) 66 (52, 85)  < 0.0001 
Censored 0 0  
Cross-clamp time (minutes) 65 (53, 76) 49 (39, 64)  < 0.0001 
Censored 0 0  
Surgery duration (minutes) 163 (139, 190) 149 (114, 167)  < 0.0001 
Censored 3 4  
*Log-rank test. Seven surgery durations were not recorded and censored at 1 minute.  492 
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Table 3. Costs, QALYs and cCost-effectiveness 494 
 Cost and QALYs  
(with imputation)  
 
FS (n = 118) MS (n = 104) 
Mean Cost 
per patient 
SD Mean Cost 
per patient 
SD 
Primary Admission 
Costs 
Theatre use £3,824 £1,243 £4,422 £2,053 
Additional surgical items £16.52 £0.0 £52.0 £0.0 
Critical care (ITU) £1,834 £3,023 £2,934 £5,030 
Cardiac ward £2,744 £1,664 £2,676 £1,500 
Physio- and Occupational Therapy £77 £55 £78 £68 
Rehabilitation £384 £1,878 £263 £1,621 
Acute hospital £347 £1,919 £298 £1,971 
Sub-total cost £9,226 £6,511 £10,724 £8,850 
Post primary 
admission costs to 
12 months 
Hospital Re-admission £418 £1,475 £575 £1,863 
Follow up tests £224 £258 £282 £279 
Follow up healthcare visits £373 £359 £311 £263 
           Sub-total cost £1,015 £1,778 £1,168 £2,079 
 
Drugs 
 
£379 
 
£548 
 
£441 
 
£977 
Total cost over 12 months £10,620 £7,624 £12,333 £9,864 
Incremental cost- 
effectiveness*  
(probabilistic 
analysis with 
Incremental cost at 12 months (MS-FS) £2,154.0 (SE £36) 
Incremental EQ-5D-3L QALYs (MS-FS) -0.0122 (SE 0.0008) 
ICER MS dominated by FS 
NMB (at WTP £20,000/QALY) -£2,397 
NMB (at WTP £30,000/QALY) -£2,519 
Formatted: Font color: Auto
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baseline 
adjustment) 
SD: standard deviation, SE: standard error, WTP: willingness to pay, NMB: net monetary benefit, ICER: incremental 
cost-effectiveness ratio.  * Incremental costs and effects estimated using SUR, adjusting for baseline differences. 
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 QALYs and cost-effectiveness  495 
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 496 
 Cost and QALYs  
(with imputation)  
 
FS (n = 118) MS (n = 104) 
Mean Cost 
per patient 
SD Mean Cost 
per patient 
SD 
Primary Admission 
Costs 
Theatre use £3,824 £1,243 £4,422 £2,053 
Additional surgical items £16.52 £0.0 £52.0 £0.0 
Critical care (ITU) £1,834 £3,023 £2,934 £5,0309 
Cardiac ward £2,744 £1,664 £2,676 £1,500 
Physio- and Occupational 
Therapy 
£77 £55 £78 £68 
Rehabilitation £384 £1,878 £263 £1,621 
Acute hospital £347 £1,919 £298 £1,971 
Sub-total cost £9,226 £6,511 £10,724 £8,850 
Post primary 
admission costs to 12 
months 
Hospital Re-admission £418 £1,475 £575 £1,863 
Follow up tests £224 £258 £282 £279 
Follow up healthcare visits £373 £359 £311 £263 
Drugs £379 £548 £441 £977 
Total cost over 12 months £10,620 £7,624 £12,333 £9,864 
Incremental cost- 
effectiveness*  
(probabilistic analysis 
with baseline 
adjustment) 
Incremental cost at 12 months (MS-FS) £2,154.0 (SE £36) 
Incremental EQ-5D-3L QALYs (MS-FS) -0.0122 (SE 0.0008) 
ICER MS dominated by FS 
NMB (at WTP £20,000/QALY) -£2,397 
NMB (at WTP £30,000/QALY) -£2,519 
SD: standard deviation, SE: standard error WTP: willingness to pay, NMB: net monetary benefit, ICER: incremental 
cost-effectiveness ratio.  * Incremental costs and effects estimated using SUR, adjusting for baseline differences. 
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Appendix A: Statistical Analysis 
 
 
Table A1. All patients who underwent a redo sternotomy, or crossed over from mini- to full sternotomy, or 
were randomised but found to be ineligible 
 
 Allocated 
treatment Description 
Per-protocol 
population 
Safety 
population 
     
Redos  FS Return to theatre for ventricular septal defect closure and redo-AVR. As FS As FS 
 FS Return to theatre for tamponade and cardiac arrest. Redo sternotomy for 
tamponade. 
As FS As FS 
 MS Return to theatre for tamponade MA bleed. Conversion to FS. As MS As MS 
 MS Return to theatre for bleeding. Redo FS. As MS As MS 
 MS Return to theatre for tamponade. Evacuation of clot/pericardial effusion. 
Conversion to FS. 
As MS As MS 
 MS Return to theatre for cardiac arrest and tamponade. Emergency re-
sternotomy (FS), tamponade and aortotomy repair. 
As MS As MS 
 MS Return to theatre for pericardial collection and early tamponade. PEA arrest. 
Re-exploration on bypass. Completion FS. 
As MS As MS 
 MS Second return to theatre. Attempted weaning of ECMO and placement of 
RVAD. Removal of blood clot. Redo sternotomy. 
As MS As MS 
     
Crossovers  MS Aortic root replacement required, FS indicated. Excluded As FS 
 MS FS indicated as unable to perform TOE. Excluded As FS 
 MS Aorta interposition graft required. Excluded As MS 
 MS FS indicated as unable to have TOE. Excluded As FS 
 MS Needed CABG due to intraoperative injury. Excluded As MS 
 MS Needed CABG due to intraoperative injury. Excluded As MS 
 MS FS indicated as unable to perform TOE. Excluded As FS 
 MS Required aortic root replacement, conversion to FS. Excluded As MS 
 MS Patient randomised too early - unable to insert TOE probe. Excluded As FS 
 MS Did not have correct equipment in theatre. Excluded As FS 
 MS Mini-sternotomy equipment not available. Excluded As FS 
 MS Bleeding. Excluded As MS 
 MS Patient had calcified aorta. Nowhere to cannulate safely.  Excluded As MS 
     
Ineligible FS Withdrawn from trial by surgeon pre-operatively (but post-randomisation) as 
required AVR and myectomy. 
Excluded Excluded 
 FS Poor quality baseline echocardiogram, with no assessment of LV function. Excluded As FS 
 MS Surgeon had not checked echo report until after randomisation. Underwent 
FS. 
Excluded As FS 
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Table A2. Additional summaries of in-hospital endpoints  
 Mini-sternotomy  
(n = 118) 
Full sternotomy  
(n = 104) 
   
Time to discharge (days)   
Mean (standard error) 9.5 (0.6) 8.6 (0.5) 
Median (95% confidence interval) 7 (6, 8) 7 (6, 8) 
   
Time until fit for discharge (days)   
Mean (standard error) 8.5 (0.5)* 7.5 (0.3)* 
Median (95% confidence interval) 6 (5, 7) 6 (6, 7) 
   
Time to first mobilisation (days)   
Mean (standard error) 5.7 (0.5)* 4.9 (0.3)* 
Median (95% confidence interval) 4 (3, 4) 4 (-, -) 
   
Time to mediastinal drain removal (hours)   
Mean (standard error) 48.1 (4.8)* 30.0 (1.7) 
Median (95% confidence interval) 26.1 (22.8, 42.6) 22.5 (22.0, 22.9) 
   
Time to first extubation (hours)   
Mean (standard error) 13.1 (1.7)* 10.5 (0.7) 
Median (95% confidence interval) 9.2 (8.7, 9.9) 8.3 (8.0, 9.2) 
   
 
Table A2 shows Kaplan-Meier estimates of in-hospital endpoints. Censoring of longest time to event for some 
endpoints led to underestimation of means and standard errors (highlighted with asterisks). A confidence interval 
for median time to mobilisation could not be estimated.   
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Table A3. Additional summaries of operative endpoints 
 
 Mini-sternotomy  
(n = 118) 
Full sternotomy  
(n = 104) 
   
Theatre time (minutes)   
Mean (standard error) 201.2 (3.9) 181.0 (4.6) 
Median (95% confidence interval) 191 (187, 205) 176 (170, 180) 
   
CPB time (minutes)   
Mean (standard error) 82.0 (1.9) 69.5 (2.3) 
Median (95% confidence interval) 80 (77, 86) 66 (59, 74) 
   
Cross clamp time (minutes)   
Mean (standard error) 65.5 (1.5) 52.4 (1.6) 
Median (95% confidence interval) 65 (61, 69) 49 (45, 53) 
   
Surgery duration (minutes)   
Mean (standard error) 165.5 (3.4) 145.7 (4.3) 
Median (95% confidence interval) 163(155, 172) 148.5 (134, 153) 
   
Total theatre time, including repeats/readmissions (minutes)   
Mean (standard error) 221.1 (9.5) 191.2 (6.1) 
Median (95% confidence interval) 196 (189, 210) 178.5 (171, 188) 
   
Total CPB time, including repeats/readmissions (minutes)   
Mean (standard error) 85.1 (2.6) 71.1 (2.8) 
Median (95% confidence interval) 82 (77, 87) 66 (59, 74) 
   
Total cross clamp time, including repeats/readmissions (minutes)   
Mean (standard error) 66.1 (1.6) 53.5 (2.0) 
Median (95% confidence interval) 66 (61, 70) 49 (45, 53) 
   
Volume of blood lost in the first 12 postoperative hours (ml)   
Mean (SD) 310.4 (342.5) 323.2 (267.8) 
Median (quartiles) 225 (150, 325) 250 (175, 375) 
   
Transfusion of packed red cells in the first 48 postoperative hours (ml)   
Number of transfused patients (%)  50 (42%) 51 (49%) 
Mean (SD) in transfused patients 625.3 (513.2) 442.4 (265.3) 
Median (quartiles) in transfused patients  500 (300, 644)  303 (284, 569) 
   
Transfusion of clotting products in the first 48 postoperative hours (ml)   
Number of transfused patients (%) 11 (9%) 4 (4%) 
Mean (SD) in transfused patients  920.5 (1438.4) 753.0 (672.5) 
Median (quartiles) in transfused patients  332 (183, 1050) 625 (209, 1297) 
   
 
All estimates for time-to-event endpoints in Table A3 are Kaplan-Meier estimates. Time data were complete, 
except for seven surgery durations (3 MS, 4 FS) that were not recorded and were therefore censored at 1 minute. 
Blood data were only missing for one patient (FS group, withdrawn before surgery). Blood transfusion and 
clotting products data for seven patients at the Freeman hospital were recorded in units and converted to ml (1 
unit PRC = 300ml, 1 unit platelets = 245ml, 1 unit FFP = 280ml). Transfusion data were explored using logistic 
regression models, including fixed effects for treatment, valve and sex, and a random surgeon effect. These 
analyses did not show a statistically significant difference between MS and FS patients in either need for blood 
transfusion (MS/FS odds ratio 0.797, confidence interval 0.453 to 1.402, p-value 0.4310) or the need for 
transfusion of clotting products (MS/FS odds ratio 2.616, confidence interval 0.801 to 8.541, p-value 0.1112). 
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Table A4. Results from Cox models and log-rank tests for primary and secondary endpoints 
 
 
MS/FS hazard ratio  
(95% confidence interval) 
p-value for null 
hypothesis HR = 1 
Log-rank 
test statistic 
p-value from 
log-rank test 
     
Primary analyses     
Time to discharge 0.874 (0.668,1.143) 0.3246 0.157 0.6924 
Time until fit 0.907 (0.688,1.197) 0.4914 0.340 0.5597 
     
Per protocol analyses of primary endpoints     
Time to discharge 0.868 (0.656,1.147) 0.3194 0.200 0.6544 
Time until fit 0.915 (0.688,1.218) 0.5443 0.217 0.6415 
     
Sensitivity analyses: 
age included as an effect in the Cox models 
    
Time to discharge 0.866 (0.661,1.135) 0.2985 0.157 0.6924 
Time until fit 0.902 (0.683,1.192) 0.4685 0.340 0.5597 
     
Sensitivity analyses: 
EuroSCORE included as an effect in the Cox models 
    
Time to discharge 0.885 (0.676,1.159) 0.3753 0.157 0.6924 
Time until fit 0.936 (0.709,1.236) 0.6400 0.340 0.5597 
     
Sensitivity analyses: 
censoring times taken as event times: 
    
Time to discharge 0.884 (0.677,1.153) 0.3625 0.189 0.6639 
Time until fit 0.888 (0.680,1.160) 0.3844 0.765 0.3819 
     
Sensitivity analysis: 
patients assumed to be fit at discharge 
    
Time until fit 0.879 (0.671, 1.151) 0.3480 0.703 0.4018 
     
Secondary endpoint analyses     
Time until first mobilisation  0.899 (0.680,1.187) 0.4518 0.303 0.5819 
Time until drain removal 0.587 (0.442,0.778) 0.0002 5.838 0.0157 
Time until first extubation 0.856 (0.655,1.120) 0.2582 0.359 0.5488 
     
Exploratory analyses     
Surgery duration 0.660 (0.500,0.872) 0.0035 17.892 < 0.0001 
CPB time 0.592 (0.448,0.782) 0.0002 24.871 < 0.0001 
Cross clamp time 0.451 (0.340,0.597) < 0.0001 42.539 < 0.0001 
Theatre time 0.665 (0.503,0.879) 0.0042 16.806 < 0.0001 
Total CPB time including repeats/readmissions 0.547 (0.414,0.723) < 0.0001 20.176 < 0.0001 
Total cross clamp time including repeats/readmissions 0.458 (0.346,0.608) < 0.0001 34.352 < 0.0001 
Total theatre time including repeats/readmissions 0.698 (0.531,0.918) 0.0102 5.657 0.0174 
Time to death by any cause 1.871 (0.723, 4.844) 0.1966 0.7309 0.3926 
     
 
Table A4 shows the results of all analyses performed for the primary and secondary time-to-event endpoints, 
including unplanned, exploratory analyses of secondary endpoints. All secondary endpoint analyses, sensitivity 
analyses and exploratory analyses were performed using the intent to treat population. All log-rank tests were 
stratified by valve, sex and surgeon. All Cox models included valve, sex and treatment as fixed effects, and 
surgeon as a random effect. Exploratory analysis of time to all-cause death included age as a fixed effect in the 
Cox model. Mean imputation was used for missing EuroSCORE data at baseline (1 MS).     
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Table A5.  Summaries of pain at rest scores in the first ten days following surgery 
 
  Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
    
Day 1 Mean (SD) 3.5 (2.5) 3.7 (2.4) 
 n  100 (85%) 82 (80%) 
    
Day 2 Mean (SD) 3 (2.3) 3.1 (2.5) 
 n  89 (75%) 81 (79%) 
    
Day 3 Mean (SD) 2.7 (2.3) 2.4 (2.3) 
 n  91 (77%) 83 (81%) 
    
Day 4 Mean (SD) 2.4 (2.1) 2.4 (2.4) 
 n  94 (80%) 84 (82%) 
    
Day 5 Mean (SD) 2 (1.9) 2.1 (2) 
 n 90 (79%) 80 (79%) 
    
Day 6 Mean (SD) 1.8 (1.7) 2.1 (2) 
 n  69 (77%) 61 (76%) 
    
Day 7 Mean (SD) 1.5 (1.8) 1.8 (2) 
 n  46 (69%) 42 (78%) 
    
Day 8 Mean (SD) 1.2 (1.4) 1.7 (1.6) 
 n  40 (77%) 35 (76%) 
    
Day 9 Mean (SD) 1 (1.8) 0.8 (1.5) 
 n  25 (57%) 18 (47%) 
    
Day 10 Mean (SD) 0.7 (1) 1.3 (2) 
 n  18 (47%) 12 (43%) 
    
 
Table A5 shows the number of pain scores taken for each of the 10 days following surgery. The denominator 
used for each percentage is the number of patients known to be alive and in hospital on the given day.  
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Table A6.  Summaries of EQ-5D utility scores up to the 12 month follow-up 
 
  Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
    
Baseline Mean (SD) 0.77 (0.19) 0.70 (0.24) 
 n  105 (89%) 95 (91%) 
    
Day 4 Mean (SD) 0.47 (0.29) 0.39 (0.28) 
 n  92 (78%) 89 (86%) 
    
Discharge Mean (SD) 0.60 (0.24) 0.58 (0.24) 
 n  103 (87%) 88 (85%) 
    
Six weeks Mean (SD) 0.74 (0.23) 0.71 (0.21) 
 n  106 (90%) 88 (85%) 
    
Six months Mean (SD) 0.83 (0.25) 0.83 (0.23) 
 n 105 (89%) 95 (91%) 
    
Twelve months Mean (SD) 0.83 (0.29) 0.78 (0.28) 
 n 103 (87%) 84 (81%) 
    
 
For patients who died, EQ-5D scores were taken to be zero following death. Percentages presented in Table A6 
were calculated as the number of scores recorded (including the zeros) divided by the number of patients 
randomised to the group. The difference in mean baseline score was potentially due to the imbalance in gender 
(the FS group has a greater proportion of females, who reported lower quality of life on average).  
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Table A7.  Summaries of SF-36 domain scores up to the 12 month follow up 
 
   Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
 
Bodily pain Baseline Mean (SD) 70 (25) 64 (28) 
  n 104 (88%) 96 (92%) 
 Six weeks Mean (SD) 61 (24) 60 (23) 
  n 105 (89%) 90 (87%) 
 Six months Mean (SD) 79 (27) 74 (28) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 76 (31) 72 (32) 
  n 99 (84%) 86 (83%) 
 
General health Baseline Mean (SD) 62 (20) 58 (22) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 70 (20) 66 (20) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 71 (24) 66 (24) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 68 (26) 62 (26) 
  n 100 (85%) 86 (83%) 
 
Mental health Baseline Mean (SD) 74 (18) 67 (21) 
  n 104 (88%) 95 (91%) 
 Six weeks Mean (SD) 72 (22) 73 (19) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 80 (21) 74 (22) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 76 (26) 73 (23) 
  n 100 (85%) 86 (83%) 
 
Physical functioning Baseline Mean (SD) 54 (26) 47 (28) 
  n 105 (89%) 96 (92%) 
 Six weeks Mean (SD) 63 (22) 56 (23) 
  n 105 (89%) 91 (88%) 
 Six months Mean (SD) 78 (27) 70 (28) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 74 (30) 67 (31) 
  n 100 (85%) 86 (83%) 
 
Role emotional Baseline Mean (SD) 67 (40) 55 (46) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 60 (44) 63 (43) 
  n 104 (88%) 90 (87%) 
 Six months Mean (SD) 81 (35) 72 (42) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 76 (39) 71 (42) 
  n 98 (83%) 85 (82%) 
     
Role physical Baseline Mean (SD) 33 (41) 23 (38) 
  n 103 (87%) 96 (92%) 
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 Six weeks Mean (SD) 19 (32) 20 (33) 
  n 103 (87%) 90 (87%) 
 Six months Mean (SD) 65 (42) 59 (44) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 64 (44) 52 (46) 
  n 98 (83%) 85 (82%) 
 
Social functioning Baseline Mean (SD) 66 (30) 61 (29) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 66 (29) 68 (27) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 85 (26) 78 (28) 
  n 102 (86%) 93 (89%) 
 Twelve months Mean (SD) 81 (30) 78 (30) 
  n 98 (83%) 85 (82%) 
 
Vitality Baseline Mean (SD) 46 (25) 40 (23) 
  n 104 (88%) 95 (91%) 
 Six weeks Mean (SD) 50 (22) 48 (22) 
  n 104 (88%) 90 (87%) 
 Six months Mean (SD) 64 (23) 57 (23) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 60 (26) 54 (26) 
  n 100 (85%) 86 (83%) 
     
 
An in-house implementation of the standard scoring algorithm for the developmental version of SF-36 was used. 
For patients who died, SF-36 scores were taken to be zero following death. Percentages presented in Table A7 
were calculated as the number of scores recorded (including the zeros) divided by the number of patients 
randomised to the group. The differences in mean baseline scores were potentially due to the imbalance in 
gender (the FS group has a greater proportion of females, who reported lower quality of life on average).  
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Table A8. Estimated treatment effects (MS - FS) and treatment-time interactions for SF-36 domain scores 
up to 12 months, EQ-5D utility scores up to 12 months and pain scores up to discharge 
 
 Effect (MS – FS) 95% confidence interval p-value 
    
Pain at rest (n = 219)    
Treatment effect 0.0 (-0.7, 0.6) 0.9766 
Treatment-time (days) interaction  0.0 (-0.1, 0.1) 0.8190 
    
EQ-5D utility scores (n = 197)    
Treatment effect 0.02 (-0.03, 0.07) 0.5148 
Treatment-time (months) interaction 0.00 (-0.01, 0.01) 0.9731 
    
SF-36 physical functioning (n = 192)    
Treatment effect 1.2 (-6.2, 8.7) 0.7414 
Treatment-time (months) interaction 0.3 (-0.2, 0.9) 0.2387 
    
SF-36 role physical (n = 190)    
Treatment effect -8.3 (-21.1, 4.5) 0.2025 
Treatment-time (months) interaction 1.7 (0.3, 3.1) 0.0169 
    
SF-36  bodily pain (n = 191)    
Treatment effect -0.7 (-9.1, 7.8) 0.8792 
Treatment-time (months) interaction 0.3 (-0.5, 1.1) 0.4331 
    
SF-36  general health (n = 189)    
Treatment effect -1.0 (-7.5, 5.5) 0.7710 
Treatment-time (months) interaction 0.3 (-0.2, 0.8) 0.2224 
    
SF-36  vitality (n = 190)    
Treatment effect -2.1 (-8.8, 4.5) 0.5273 
Treatment-time (months) interaction 0.6 (0.1, 1.2) 0.0293 
    
SF-36  social functioning (n = 189)    
Treatment effect -5.5 (-14.1, 3.1) 0.2093 
Treatment-time (months) interaction 1.0 (0.2, 1.7) 0.0183 
    
SF-36  role emotional (n = 189)    
Treatment effect -6.2 (-18.6, 6.2) 0.3255 
Treatment-time (months) interaction 1.1 (-0.1, 2.3) 0.0699 
    
SF-36 mental health (n = 190)    
Treatment effect -3.2 (-9.7, 3.4) 0.3431 
Treatment-time (months) interaction 0.5 (-0.0, 1.0) 0.0702 
    
 
Table A8 shows results of complete case analyses of questionnaire data, under a missing completely at random 
assumption, including only patients with at least one analysable follow-up questionnaire. For each analysis, the 
n in parentheses is number of patients used to fit the model. For pain and SF-36 scores, some random effects 
were estimated to have a variance of 0 and were excluded from the models (surgeon effect for pain, and both the 
surgeon effect and random slope for SF-36). The slope (time coefficient) was estimated to be negative for pain 
and positive for all EQ-5D and SF-36 scores. This suggests improvement over time in each score. Evidence of 
greater rate of improvement over time for MS patients (statistically significant, positive interaction term) was 
seen for three SF-36 domains (role physical, vitality, and social functioning), but no others. 
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Table A9. Estimated treatment effects (MS-FS) and treatment-time interactions for SF-36 domain scores 
up to 12 months, EQ-5D utility scores up to 12 months and pain scores up to discharge, after multiple 
imputation of missing scores 
 
 Effect (MS – FS) 95% confidence interval p-value 
    
Pain at rest    
Treatment effect 0.0 (-0.7, 0.6) 0.9059 
Treatment-time (days) interaction 0.0 (-0.1, 0.1) 0.9685 
    
EQ-5D utility scores    
Treatment effect 0.01 (-0.04, 0.06) 0.8203 
Treatment-time (months) interaction 0.00 (-0.01, 0.01) 0.9094 
    
SF-36 physical functioning    
Treatment effect 2.0 (-4.9, 8.9) 0.5744 
Treatment-time (months) interaction 0.2 (-0.3, 0.8) 0.3996 
    
SF-36 role physical     
Treatment effect -6.6 (-18.7, 5.4) 0.2808 
Treatment-time (months) interaction 1.5 (0.1, 2.8) 0.0310 
    
SF-36  bodily pain     
Treatment effect -0.1 (-9.0, 7. 7) 0.9748 
Treatment-time (months) interaction 0.3 (-0.4, 1.1) 0.4091 
    
SF-36  general health     
Treatment effect 1.1 (-5.0, 7.3) 0.7175 
Treatment-time (months) interaction 0.2 (-0.3, 0.7) 0.3373 
    
SF-36  vitality    
Treatment effect -0.5 (-6.9, 5.9) 0.8798 
Treatment-time (months) interaction 0.4 (-0.2, 1.0) 0.1733 
    
SF-36  social functioning    
Treatment effect -4.4 (-12.4, 3.5) 0.2756 
Treatment-time (months) interaction 0.7 (0.0, 1.5) 0.0589 
    
SF-36  role emotional    
Treatment effect -4.6 (-16.4, 7.2) 0.4415 
Treatment-time (months) interaction 0.8 (-0.4, 2.0) 0.1790 
    
SF-36 mental health     
Treatment effect -2.5 (-8.6, 3.5) 0.4113 
Treatment-time (months) interaction 0.4 (-0.1, 0.9) 0.1195 
    
 
Table A9 shows the results from analysing the questionnaire data using multiple imputation to handle missing 
observations, under a missing at random assumption. For each analysis, missing data were imputed from models 
that included all other variables used in the analysis, along with CCS grading and NYHA grading as auxiliary 
variables. The method used was multiple imputation by chained equations with predictive mean matching. 
Estimates from 100 imputed data sets were combined using Rubin’s rules. Pain was only imputed for patients 
known to be alive and in hospital, not for patients who had died or had already been discharged. Evidence of 
greater rate of improvement over time for MS patients (statistically significant, positive interaction term) was 
seen only for one SF-36 domain.  
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Figure A1. Forest plots of mean pain scores for the first 10 days following surgery, with 95% confidence 
intervals 
 
In Figure A1, means on each day were adjusted for sex and valve type, and were estimated from the complete 
case analysis. 
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Figure A2. Forest plot of mean EQ-5D scores at each follow-up time, with 95% confidence intervals 
 
In Figure A2, means at each follow-up time were adjusted for baseline EQ-5D, sex and valve type, and were 
estimated from the complete case analysis.  
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Figure A3. Forest plot of mean SF36 domain scores at each follow-up time, with 95% confidence intervals 
 
In Figure A3, means at each follow-up time were adjusted for baseline domain score, sex and valve type, and 
were estimated from the complete case analysis. A score of 100 represents no disability, and a score of 0 
represents maximum disability. 
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 Table A10. Summaries heart function (LVEF) and respiratory function (FEV1) 
 
 Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
   
FEV1 (litres):   
   
Baseline visit   
Mean (SD) 2.3 (0.7) 2.3 (0.8) 
Median (quartiles) 2.2 (1.8, 2.7) 2.2 (1.7, 2.6) 
n 115 101 
   
Discharge    
Mean (SD) 1.6 (0.6) 1.6 (0.6) 
Median (quartiles) 1.5 (1.2, 1.8) 1.5 (1.2, 1.9) 
n 82 69 
   
6 week visit   
Mean (SD) 2.1 (0.8) 2.1 (0.7) 
Median (quartiles) 2 (1.5, 2.5) 1.9 (1.6, 2.5) 
n 92 84 
   
6 month visit   
Mean (SD) 2.2 (0.7) 2.1 (0.7) 
Median (quartiles) 2.1 (1.7, 2.6) 1.9 (1.4, 2.4) 
n 91 82 
   
   
LVEF (%):   
   
Baseline visit   
Mean (SD) 61.9 (9.1) 62.4 (8.6) 
Median (quartiles) 62.5 (57.5, 67.5) 63 (57.5, 67.0) 
n 117 101 
   
Discharge   
Mean (SD) 59.9 (9.7) 59 (10.2) 
Median (quartiles) 62 (55.0, 65.0) 58 (55.0, 64.5) 
n 106 96 
   
6 month visit   
Mean (SD) 61.2 (8.1) 61.8 (9.7) 
Median (quartiles) 61 (56.0, 67.5) 62.5 (56.3, 68.0) 
n 97 88 
   
 
FEV1 is forced expiratory volume in one second, measured by hand-held spirometry. LVEF is left ventricular 
ejection fraction, measured by echocardiography. No analyses were planned for these endpoints. 
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Table A11. Frequency of non-fatal SAEs (number of patients) within one year of surgery, by treatment 
received  
  Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Cardiac (including atrial fibrillation, conduction 
problems, need for permanent pacemaker) 
43 (29) 
 
27 (21) 
 
70 (50) 
 
Respiratory 20 (14) 9 (8) 29 (22) 
Injury/procedural 19 (11) 7 (6) 26 (17) 
Non-cardiorespiratory infection (including wound)  7 (7) 12 (9) 19 (16) 
Urinary 11 (10) 8 (6) 19 (16) 
Surgical and medical procedures 9 (6) 7 (7) 16 (13) 
Nervous system 8 (8) 7 (7) 15 (15) 
Cardiorespiratory infection (including endocarditis, 
device-related infections, chest infection) 
9 (9) 6 (5) 15 (14) 
Vascular 9 (9) 1 (1) 10 (10) 
Psychiatric 5 (5) 5 (5) 10 (10) 
Gastro-intestinal – diarrhoea 7 (6) 3 (3) 10 (9) 
Gastro-intestinal – other 7 (7) 1 (1) 8 (8) 
General disorders 4 (4) 3 (2) 7 (6) 
Metabolic 2 (2) 3 (2) 5 (4) 
Blood/lymph 4 (3) 1 (1) 5 (4) 
Neoplasms 1 (1) 1 (1) 2 (2) 
Hepatitis/cholecystitis 1 (1) 1 (1) 2 (2) 
Musculoskeletal 2 (2) 0 (0) 2 (2) 
Skin/tissue 0 (0) 1 (1) 1 (1) 
Eye 0 (0) 1 (1) 1 (1) 
Immune 0 (0) 1 (1) 1 (1) 
    
Total 168 (56) 105 (46) 273 (102) 
    
 
Among the nervous system SAEs recorded in Table A11, strokes were suffered by 3 FS recipients and 2 MS 
recipients. No patient suffered more than one stroke.
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Table A12. Frequencies of non-death SAEs (and number of patients experiencing them), within a year of 
surgery, at each level of severity, expectedness and relatedness, by treatment received 
  
 Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Cardiorespiratory:    
    
Severity    
Severe 26 (14) 14 (11) 40 (25) 
Moderate 34 (24) 24 (18) 58 (42) 
Mild 12 (11) 4 (4) 16 (15) 
    
Expectedness    
Expected 69 (38) 42 (30) 111 (68) 
Unexpected 3 (2) 0 (0) 3 (2) 
    
Relatedness    
Probably related 4 (4) 2 (2) 6 (6) 
Possibly related 50 (30) 32 (25) 82 (55) 
Unrelated 18 (13) 8 (6) 26 (19) 
    
Total 72 (38) 42 (30) 114 (68) 
    
    
Non-cardiorespiratory:    
    
Severity    
Severe 40 (21) 24 (15) 64 (36) 
Moderate 43 (29) 31 (21) 74 (50) 
Mild 13 (11) 8 (5) 21 (16) 
    
Expectedness    
Expected 68 (34) 45 (27) 113 (61) 
Unexpected 28 (15) 18 (15) 46 (30) 
    
Relatedness    
Probably related 9 (5) 5 (5) 14 (10) 
Possibly related 37 (22) 30 (20) 67 (42) 
Unrelated 50 (27) 28 (20) 78 (47) 
    
Total 96 (41) 63 (34) 159 (75) 
    
 
The only unexpected events in the MS group were a bilateral pleural effusion in one patient, and bronchial 
aspiration and peri-arrest event in another. Both patients completely recovered. Exploratory analysis in the 
safety population, using logistic regression (with fixed treatment, valve and sex effects, and a random surgeon 
effect), did not show a statistically significant difference between MS and FS recipients in the odds of suffering 
a non-death SAE within the first year (MS/FS odds ratio 1.559, confidence interval 0.895 to 2.715 and p-value 
0.1161). An exploratory Poisson regression (with a fixed effect for treatment and a random patient effect) did 
show a greater rate of such SAEs for MS recipients (MS/FS rate ratio 1.615, confidence interval 1.070 to 2.437, 
p-value 0.0225). There were 7 pericardial tamponades in total (4 for FS recipients, 3 for MS recipients, only one 
per patient), but logistic regression (without the random surgeon effect) did not produce a statistically significant 
result (MS/FS odds ratio 0.680, confidence interval 0.146 to 3.178, p-value 0.6229). 
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Table A13. Frequency of paraprosthetic regurgitation, by treatment received 
 
 Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Discharge    
No regurgitation 84 85 169 
Mild regurgitation 19 16 35 
Moderate regurgitation 0 0 0 
Severe regurgitation 0 0 0 
n 101 103 204 
    
6 month visit    
No regurgitation 77 82 159 
Mild regurgitation 18 10 28 
Moderate regurgitation 0 0 0 
Severe regurgitation 0 0 0 
n 95 92 187 
    
 
Paraposthetic regurgitation was explored using logistic regressions at each time point. These were performed as 
complete case analyses, in the safety population. Logistic regression models included fixed treatment, valve and 
sex effects, and a random surgeon effect. They did not show a statistically significant difference between MS 
recipients and FS recipients in the odds of regurgitation, either at discharge (MS/FS odds ratio 1.163, confidence 
interval 0.553 to 2.445, p-value 0.6883) or at 6 months (MS/FS odds ratio 1.880, confidence interval 0.798 to 
4.430, p-value 0.1480). 
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Table A14. All wound infections within the first year after surgery, by treatment received 
 
Treatment 
received Relationship Description 
   
FS Possibly related Superficial sternal wound infection. 
FS Possibly related Sternal wound infection. Returned to theatre for debridement and 2x wires removed. 
FS Possibly related Sternal wound infection. 
FS Possibly related Sternal wound breakdown. Debridement and excision of sinuses.  PICC line inserted for 6 weeks 
IV antibiotics. 
FS Possibly related Drain site wound infection. 
FS Possibly related Wound infection - small area at lower end of sternum. 
FS Possibly related Small sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Possibly related Sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Possibly related Sternal wound infection. Antibiotics commenced. 
FS Possibly related Sternal wound infection - requiring hospital admission. Treated with antibiotics. 
FS Possibly related Wound Infection. Commenced on antibiotics and daily dressings. 
   
MS Possibly related Readmission, wound infection, iv/oral flucloxacillin. 
MS Possibly related MRSA sternal wound infection. 
MS Probably related Sternal wound infection. Admitted to NGTH with fever, chest pain, SOB and discharging sternal 
wound. Commenced IV flucloxacillin. Swab taken, VAC dressing applied. 
MS Possibly related Wound infection at base of sternotomy. Wound swab taken, grown K.pneumoniae. Commenced 
antibiotics - amoxycillin. 
   
 
In total, 4 MS recipients and 13 FS recipients suffered wound infections within a year of surgery (one FS 
recipient suffered two infections). No patients who received a mechanical valve suffered a wound infection. 
Odds of wound infection were explored via logistic regression (complete case analysis in the safety population, 
with fixed treatment and sex effects, and with a random surgeon effect). The odds of suffering at least one 
wound infection were estimated to be lower for MS recipients than for FS recipients (MS/FS odds ratio 0.312, 
confidence interval 0.097 to 1.005, p-value 0.0511). Only two infections were categorised as deep (1 MS, 1FS).  
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Table A15. All deaths 
 
 Treatment 
received 
Treatment 
allocated 
Cause Relationship to 
treatment 
Days from 
surgery to death 
      
Cardiorespiratory  FS FS Endocarditis and sepsis. Possibly related 124 
 FS FS Lung infection. Unrelated 1050 
 FS FS Respiratory failure, pneumonia, chronic lymphocytic leukaemia. Unrelated 1057 
      
 MS MS Cardiac arrest and pericardial tamponade 2 days after surgery. 
Heart failure and left anterior pneumothorax 3 days after surgery.  
Possibly related 3 
 MS MS Type 2 respiratory failure and shock, multi-organ failure. Possibly related 24 
 MS MS Post-op arrest on HDU on day of surgery. Heart failure 26 days 
after surgery. 
Possibly related 26 
 MS MS Lower respiratory tract infection. Type 2 respiratory failure. 
NSTEMI during hospital admission. 
Unrelated 75 
 MS MS Endocarditis, infected valve. Refused all treatment including 
antibiotics. Palliation only.  
Possibly related 241 
 MS MS Exacerbation of COPD. Unrelated 307 
 MS MS Ischaemic heart disease. Unrelated 502 
 MS MS Myocardial infarction. Unrelated 933 
      
Non-cardiorespiratory FS FS Sepsis. Unrelated 66 
 FS FS Metastatic prostate cancer. Unrelated 256 
 FS FS B cell lymphoma. Unrelated 308 
 FS FS Embolus of left common femoral artery, advanced colorectal 
cancer, AS, CHF. 
Unrelated 958 
      
 MS MS Metastatic bladder cancer. Unrelated 257 
 MS MS Death due to malignant tumour of oesophagus Unrelated 445 
 MS MS Diffuse large B cell lymphoma. Unrelated 527 
 MS MS Spontaneous subdural haemorrhage. Unrelated 873 
      
 
Table A15 shows that none of the patients who died were considered to be crossovers from MS to FS. However, 
there were three deaths among patients who were allocated and received MS but who were returned to theatre 
for redo FS. These were the deaths, all categorised as cardiorespiratory in Table A15, which occurred at 3, 26 
and 933 days after surgery. 
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Figure A4. Kaplan-Meier curves for time to death by any cause 
 
 
Patients are grouped by the treatment allocated to them. Patients who had no fatal events recorded were 
censored at the last time they were known to be alive. Times of censoring are indicated by points on the curves.  
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Appendix B: Economic Evaluation 
 
 
Introduction 
 
This trial collected data on resource and health service use for each patient during their in-patient stay through to 
the end of follow-up at 1 year.  The economic analysis compared the costs and quality of life impacts of full and 
mini-sternotomy and assessed the cost-effectiveness of mini-sternotomy as an alternative to full median 
sternotomy. 
 
The methods section first presents the unit costs, resource use data and the methods used to aggregate resource 
use and utility data at a patient level.  The methods used to document and impute missing data follow.  The last 
part describes the construction of incremental cost-effectiveness ratios and representation of uncertainty. 
 
Results are presented first for raw data (with and without imputation) for costs and QALYs separately, followed 
by estimations of costs and QALYs that account for baseline differences. The final section provides results of 
probabilistic and deterministic sensitivity analyses. 
 
Methods 
 
Unit costs 
All resource use data collected formed part of the patient-specific case-report form.  Trained research nurses 
extracted data for inpatient stays from individual patient records.  Face-to-face interviews with patients, by 
research nurses, provided data for quality of life as well as health service use during follow-up. 
 
Multiplying the unit costs by each unit of resource use and summing these resource costs across each patient’s 
12 month follow-up from date of operation enabled aggregation of total cost per patient. Table B1 provides the 
unit costs used, with source of data.  Where possible, national estimates of unit prices were used (e.g. PSSRU 
2015 [1], NHS Ref 2014-15 [2]) to increase generalisability. 
 
All resources were used once by patients (e.g. a GP visit or specific test), with the exception of two capital items 
used during surgery; the horizontal saw and defibrillator handles, both acquired for mini-sternotomy.  These 
costs were apportioned, using clinical opinion, to each patient assuming a lifespan of 20 years and that surgeons 
undertake a total of 255 mini-sternotomies over five years.  
  
Table B1.  Unit costs 
 
Item Source Consultation time/Codes Mean 
2014/15 
SD 
GP Visits PSSRU 2015. 10.8b Per patient contact lasting 17.2 
minutes 
£65.00 £13.00 
GP Home Visits PSSRU 2015. 10.8b Per patient contact lasting 11.7 
minutes  
£45.00 £9.00 
Nurse (GP Practice) Visits PSSRU 2015. 10.6 Per patient contact 15.5 minutes £14.47 £2.89 
Nurse (Specialist Community) 
Home Visits 
PSSRU 2015. 10.4 Per patient contact 15.5 minutes  £19.38 £3.88 
Physiotherapy (outpatient) NHS Ref 2014-15 Code: WF01A £16.13 £3.23 
Occupational Therapy (outpatient) NHS Ref 2014-15 Code: WF01A £16.67 £3.33 
Physiotherapy (inpatient) PSSRU 2015. 13.1 Per patient contact lasting 20 
minutes 
£12.67 £2.53 
Occupational Therapy (inpatient) PSSRU 2015. 13.2 Per patient contact lasting 20 
minutes 
£12.67 £2.53 
Physiotherapy (home) PSSRU 2015. 8.4.1 Per patient contact lasting 20 
minutes 
£27.00 £5.40 
Theatre use Papworth estimate   £20.00 £4.00 
Horizontal surgical saw Papworth estimate 
 
 
 
20 year life span and are used in 
255 surgeries in every 5 years 
 
£3,138.22  £3.1 
Paediatric internal cardioversion 
paddles 
£161.71  £0.2 
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Internal paddle handle £670.00  £0.7 
Reprocessing cost of defibrillator 
paddles for each surgery* 
Per patient £2.40 £2.40 
Single use saw blade for mini-
sternotomy 
Per patient £15.80 £15.80 
Single use saw blade for full 
sternotomy 
Per patient £48.00 £48.00 
Adult Critical Care NHS Ref 2014-15 Total/weighted average £1,274.92 £583.33 
Specialised Ward NHS Ref 2014-15 Code: SD01A £387.96 £77.59 
General Ward NHS Ref 2014-15 Code: SD03A £103.01 £20.60 
Rehabilitation PSSRU (1.3) 2015   £158.57 £31.71 
24 hour Blood Pressure 
Monitoring 
Lovibond et al. 2011, 
[3] 
  £61.47 £12.29 
Radiography (chest) Auguste et al. 2011, [4]   £3.46 £0.69 
Echo TTE NHS Ref 2014-15 Simple Echocardiogram £83.94 £16.79 
Echo TOE NHS Ref 2014-15 Complex Echocardiogram £128.49 £25.70 
Echo Stress NHS Ref 2014-15 Complex Echocardiogram £128.49 £25.70 
24 hour ECG NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
12 hour ECG NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
Exercise Tolerance Test NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
MRI scan NHS Ref 2014-15 Total/weighted average £146.15 £56.64 
Full Pulmonary Function Testing  NHS Ref 2014-15 Code: DZ52Z £55.32 £11.06 
Cardiac Rehabilitation NHS Ref 2014-15 Code: VC38Z £97.84 £19.57 
Cardio Clinic NHS Ref 2014-15 Code: WF01A £123.02 £24.60 
Pacemaker NHS Ref 2014-15 Code: EY08E £76.32 £15.26 
Blood tests NHS Ref 2014-15 Code: DAPS08 £3.46 £0.69 
Arrhythmia clinic NHS Ref 2014-15 Total/weighted average £131.14 £26.23 
Wound clinic NHS Ref 2014-15 Code: N25AF/AN £54.93 £10.99 
A&E visit NHS Ref 2014-15 Total/weighted average £140.59 £141.05 
Computerised Tomography Scan  NHS Ref 2014-15 Total/weighted average £122.31 £48.86 
 
* The lead clinician confirmed that: defibrillator is not routinely used and that the cost of paddles should apply 
to 30% of patients; and the cost of external defibrillator plates should be excluded for mini-sternotomy as the 
plate is only used when it is not possible to insert the paddles. 
 
 
Patient-level aggregation of cost 
This section describes the aggregation of costs, by patient, for the inpatient stay, post-discharge follow-up to 12 
months and drug use. 
 
Hospital stay: The time in the hospital from randomisation to discharge was disaggregated into theatre time, 
critical care unit (CCU) stay and cardiac ward stay as shown in Table B2. The total length of stay comprised 
time spent in surgery (measured in minutes), CCU (measured in hours) and cardiac ward (measured in days).  
Theatre time included duration of re-operations where applicable (a few patients had up to two returns to 
theatre) and corresponding CCU stays were added to the CCU hours. The total stay in the hospital, calculated 
using theatre time, critical care and ward stay, was compared with direct calculation of duration using date of 
operation and date of discharge to validate the breakdown of patient stay. After discharge from hospital, the 
majority of patients were discharged home but some were referred on to acute hospitals or rehabilitation centres 
(short or long term) for more care, and the costs of this additional stay were included.  
 
Post-discharge: Resource use after discharge and up to twelve months post randomisation was collected at 6 
week, 6 month and 12 month follow-up visits, with resource use divided into three categories: hospital 
admissions, tests and healthcare visits. A total of 28 different healthcare resources were used and aggregated 
over the follow-up period. For example, if a patient reported 1 blood test in discharge to 6 week follow-up 
period, 2 blood tests between 6 week to 6 month period and none after that, resource use was costed as £10.38 
(3*£3.46) post discharge .  
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Table B2. Summary of resource use (without imputation) 
 
  Full Sternotomy Mini-sternotomy 
Primary Admission Costs Unit of 
measurement 
Obs Mean 
resource 
use/patient 
SD Obs Mean resource 
use/patient 
SD 
Theatre Minutes 104 191.19 62.15 118 221.11 102.65 
Critical care (ITU) Hours 103 34.67 57.17 118 55.24 94.69 
Cardiac ward  Days 103 7.09 4.31 118 6.90 3.87 
Rehabilitation*  Days 103 2.45 11.90 117 1.68 10.27 
Acute hospital* Days 103 0.90 4.97 117 0.74 5.09 
Physiotherapy (inpatient) Days 103 5.90 4.21 117 5.90 5.16 
Occupational therapy (inpatient) Days 103 0.17 0.58 118 0.24 0.69 
Follow-up (post discharge)               
ITU Days 81 0.00 0.00 94 0.03 0.31 
General ward Days 92 2.87 14.37 101 0.86 3.43 
Cardiac ward Days 92 0.40 1.49 100 1.15 4.32 
24 hour BP Monitoring No. of tests 80 0.16 0.56 94 0.19 1.26 
Radiography (chest) No. of tests 80 0.49 0.89 94 0.64 0.90 
Computerised Tomography Scan  No. of tests 80 0.14 0.52 94 0.15 0.51 
Echo TTE No. of tests 80 0.41 0.69 94 0.55 0.84 
Echo TOE No. of tests 80 0.03 0.22 92 0.03 0.18 
Echo Stress No. of tests 80 0.01 0.11 93 0.01 0.10 
24 hour ECG No. of tests 80 0.11 0.39 94 0.15 0.46 
12 hour ECG No. of tests 80 0.69 0.91 94 0.90 1.18 
Exercise Tolerance Test No. of tests 80 0.08 0.27 93 0.06 0.25 
MRI scan No. of tests 79 0.03 0.16 94 0.05 0.23 
Full Pulmonary Function Testing  No. of tests 80 0.05 0.22 94 0.03 0.18 
Blood test No. of tests 81 0.05 0.22 94 0.06 0.35 
A&E visit No. of visits 80 0.09 0.28 94 0.22 0.51 
Arrhythmia clinic No. of visits 80 0.03 0.16 94 0.00 0.00 
Cardiac Rehabilitation No. of visits 79 0.84 2.76 93 0.32 1.43 
Cardio Clinic No. of visits 79 0.48 0.68 94 0.49 0.73 
GP Home Visits No. of visits 79 0.23 0.64 94 0.30 0.75 
GP Visits No. of visits 80 2.00 2.34 94 2.20 2.31 
Nurse (Specialist Community) Home 
Visits 
No. of visits 80 0.31 1.12 94 0.39 1.18 
Nurse (GP Practice) Visits No. of visits 80 2.10 10.02 92 0.75 1.46 
Occupational therapy (outpatient) No. of visits 80 0.11 0.71 94 0.06 0.62 
Pacemaker No. of visits 79 0.08 0.68 93 0.06 0.38 
Physiotherapy (home) No. of visits 80 0.05 0.35 94 0.00 0.00 
Physiotherapy (outpatient) No. of visits 80 0.04 0.19 94 0.01 0.10 
Wound clinic No. of visits 80 0.06 0.29 94 0.02 0.15 
*discharged to convalescence/long term care/acute hospital instead of home 
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Drugs: Drug use was matched to a corresponding unit cost using the NHS Electronic Drug tariff [5] and BNF 
[6] to sum costs across drug type for each patient.  
 
Information on drugs administered during the primary admission was complete, with total amount of each drug 
per patient checked against patient prescriptions. However drug use post-discharge was self-reported and it was 
not possible to verify or retrieve any further data on this over the follow-up period.  
 
Health State Utilities: This data was collected using EQ-5D-3L and SF-36 questionnaires. EQ-5D-3L responses 
were converted to utility values using Dolan et al (1995) [7] and to quality-adjusted life years (QALYs) for the 
trial period using the area under the curve method. SF-36 data was mapped to SF-6D utility values based on the 
ScHARR (School of Health and Related Research, University of Sheffield) algorithm and were converted to 
QALY scores (Brazier et al 2002 [8]). A value of 0 was assigned from date of death. 
 
 
Missing data 
The patterns of missing data for resource use and utilities were tested using Pearson Chi square goodness of fit 
and Wilcoxon rank sum tests for being missing at random and completely at random using the following 
variables: age, sex, treatment and health status at baseline (EQ-5D).  The baseline characteristics assessed were 
not statistically significantly different between the two groups and multiple imputations were used for economic 
analysis. Patients were assigned zero cost and zero utility value from point of death. 
 
Hospital stay: For primary admission, there were a few item non-responses for resource use data but no 
censored data. Complete information was available on all respondents barring one participant who withdrew 
from the trial after operation.  
 
Post-discharge: The frequency of missing data for resource use after discharge is provided in Table B3 for the 
two groups. Imputation models did not converge at month twelve and resource use was aggregated over time, 
i.e. imputation was carried out for the aggregate value for each item rather than at each time period. The 
proportion of missing values in the aggregated utility data ranged from 11% to 25% in resource use post 
discharge (Table B3).  
 
Table B3. Missing follow-up resource use 
 
Follow up Resource Use Full Sternotomy   Mini-sternotomy Total 
6 weeks 
  
  
Missing 3 4 7 
Lost to follow up 4 6 10 
Dead 1 4 5 
Observations 96 104 200 
6 months 
  
  
Missing 2 5 7 
Lost to follow up 8 9 17 
Dead 2 6 8 
Observations 92 98 190 
12 months 
  
  
Missing 9 4 13 
Lost to follow up 11 13 24 
Dead 4 7 11 
Observations 80 94 174 
Total 104 118 222 
 
 
Drugs: Only drugs taken from randomisation to 12 month follow up period were accounted for (covering 3,078 
drug uses of 118 different drugs). A number of assumptions (about quantity/dose and length of administration) 
were used to minimise the degree of missing information on drugs used.  For example, when dosage or 
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frequency of dose per day was missing, the mode usage among trial participants was used or, if not available, 
the BNF dosage was used. Duration of medicinal use was calculated using start and stop dates for drugs used in 
primary admission and follow-up. However, when start/stop dates were missing, replies to a “yes/no” question 
on use of drugs at follow-up time points informed duration.  For example if a drug was taken during inpatient 
stay, 6 week, 6 month and 12 month follow up, the drug was said to be used for entire 12 month trial period. 
However further assumptions about duration of medication were used when data was less forthcoming; for 
example drugs which were being taken only at 12 month follow up, without start date or stop date specified, 
were assumed to have been taken according to prescription every day for an average of three months (based on 
expert consultation). 58 records had insufficient information on usage for such personalised manual imputation, 
requiring predictive mean matching (conditioned on patient ID and name of drug).   
 
Health State Utilities: EQ-5D-3L and SF-6D utility data were imputed at each follow-up as presented in Table 
B4, and percent of missing value ranged from 9% to 23%. Further breakdown of missing data for resource use 
and HRQoL questionnaires, and imputation required for each variable is provided in Table B4. 
 
 
Table B4. Incomplete data and imputation 
  Full Sternotomy Mini-sternotomy 
Resource Use 
Comple
te 
Incompl
ete Imputed Total 
Comple
te 
Incompl
ete Imputed Total 
Primary admission         
Theatre time (minutes) 104 0 0 104 118 0 0 118 
Critical care stay (hours) 103 1 1 104 118 0 0 118 
Cardiac ward stay (days) 103 1 1 104 118 0 0 118 
Rehabilitation days*  103 1 1 104 117 1 1 118 
Acute hospital days* 103 1 1 104 117 1 1 118 
Physiotherapy visits  103 1 1 104 117 1 1 118 
Occupational therapy visits  103 1 1 104 118 0 0 118 
Follow-up (post discharge)         
Post discharge ITU days  81 23 23 104 94 24 24 118 
Post discharge general ward stay 92 12 12 104 101 17 17 118 
Post discharge cardiac ward stay 92 12 12 104 100 18 18 118 
24 hour BP Monitoring 80 24 24 104 94 24 24 118 
Radiography (chest) 80 24 24 104 94 24 24 118 
Computerised Tomography Scan  80 24 24 104 94 24 24 118 
Echo TTE 80 24 24 104 94 24 24 118 
Echo TOE 80 24 24 104 92 26 26 118 
Echo Stress 80 24 24 104 93 25 25 118 
24 hour ECG 80 24 24 104 94 24 24 118 
12 hour ECG 80 24 24 104 94 24 24 118 
Exercise Tolerance Test 80 24 24 104 93 25 25 118 
MRI scan 79 25 25 104 94 24 24 118 
Pulmonary Function Testing  80 24 24 104 94 24 24 118 
Blood test 81 23 23 104 94 24 24 118 
A&E visit 80 24 24 104 94 24 24 118 
Arrhythmia clinic 80 24 24 104 94 24 24 118 
Cardiac Rehabilitation 79 25 25 104 93 25 25 118 
Cardio Clinic 79 25 25 104 94 24 24 118 
GP Home Visits 79 25 25 104 94 24 24 118 
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GP Visits 80 24 24 104 94 24 24 118 
Nurse (Specialist Community) 
Home Visits 
80 24 24 104 94 24 24 118 
Nurse (GP Practice) Visits 80 24 24 104 92 26 26 118 
Occupational therapy  80 24 24 104 94 24 24 118 
Pacemaker 79 25 25 104 93 25 25 118 
Physiotherapy (home) 80 24 24 104 94 24 24 118 
Physiotherapy 80 24 24 104 94 24 24 118 
Wound clinic 80 24 24 104 94 24 24 118 
EQ-5D Score         
Baseline  95 9 9 104 105 13 13 118 
4 Days Post Operation 89 15 15 104 92 26 26 118 
Discharge 88 16 16 104 103 15 15 118 
6 weeks follow-up 88 16 16 104 106 12 12 118 
6 months follow-up 95 9 9 104 105 13 13 118 
12 months follow-up 84 20 20 104 103 15 15 118 
SF-6D Score         
Baseline  89 15 15 104 101 17 17 118 
6 weeks follow-up 88 16 16 104 102 16 16 118 
6 months follow-up 90 14 14 104 102 16 16 118 
12 months follow-up 82 22 22 104 91 27 27 118 
 
 
Imputation 
Missing values were imputed conditional on sex, age, type of replacement valve used, risk classification 
measured using New York Heart Association (NYHA) Functional Classification and Canadian Cardiovascular 
Society (CCS) grading of angina. To avoid loss in efficiency, missing values for resource use and utility values 
at different time points were replaced using multiple imputations by chained equations.  
 
Chained predictive mean matching was used to replace missing data for resource use and quality of life 
variables, and a total of 20 imputed datasets were created, stratified by treatment group. The imputed resource 
use is summarised in Table B5. However while conducting probabilistic analysis using bootstrap method; 
multiple imputation was carried out only once for each iteration with a total of 1000 iterations to adequately 
retain between imputation variance. The distribution of imputed values was visually checked for comparability 
with the observed data.  
 
Table B5. Summary of resource use  
 
  Full Sternotomy Mini-sternotomy 
Primary Admission Costs Unit of 
measurement 
Obs Mean 
resource use/ 
patient 
SD Obs Mean resource 
use/ 
patient 
SD 
Theatre 
Minutes 104 191.19 62.15 118 221.11 102.65 
Critical care (ITU) 
Hours 104 34.52 56.91 118 55.24 94.69 
Cardiac ward  
Days 104 7.07 4.29 118 6.90 3.87 
Rehabilitation*  
Days 104 2.42 11.84 118 1.66 10.22 
Acute hospital* 
Days 104 0.89 4.95 118 0.77 5.08 
Physiotherapy (inpatient) 
Days 104 5.88 4.20 118 5.94 5.15 
Occupational therapy (inpatient) 
Days 104 0.17 0.58 118 0.24 0.69 
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Follow-up (post discharge)  
            
ITU 
Days 104 0.00 0.00 118 0.03 0.28 
General ward 
Days 104 2.61 13.55 118 0.77 3.20 
Cardiac ward 
Days 104 0.38 1.43 118 1.19 4.14 
24 hour BP Monitoring No. tests 
104 0.18 0.52 118 0.17 1.13 
Radiography (chest) No. tests 
104 0.55 0.87 118 0.61 0.83 
CT Scan  No. tests 
104 0.16 0.48 118 0.16 0.49 
Echo TTE No. tests 
104 0.42 0.66 118 0.56 0.79 
Echo TOE No. tests 
104 0.02 0.20 118 0.05 0.19 
Echo Stress No. tests 
104 0.01 0.10 118 0.01 0.09 
24 hour ECG No. tests 
104 0.13 0.41 118 0.16 0.44 
12 hour ECG No. tests 
104 0.72 0.85 118 0.94 1.17 
Exercise Tolerance Test No. tests 
104 0.07 0.24 118 0.06 0.23 
MRI scan 
No. tests 104 0.02 0.15 118 0.06 0.22 
Full Pulmonary Function Testing 
No. tests 104 0.06 0.22 118 0.03 0.16 
Blood test 
No. tests 104 0.06 0.21 118 0.07 0.33 
A&E visit 
No. visits 104 0.13 0.31 118 0.24 0.50 
Arrhythmia clinic 
No. visits 104 0.02 0.14 118 0.00 0.00 
Cardiac Rehabilitation 
No. visits 104 1.07 2.78 118 0.34 1.36 
Cardio Clinic 
No. visits 104 0.47 0.62 118 0.52 0.72 
GP Home Visits 
No. visits 104 0.27 0.64 118 0.25 0.68 
GP Visits 
No. visits 104 2.00 2.16 118 2.17 2.18 
Nurse (Specialist Community) 
Home Visits No. visits 104 0.38 1.06 118 0.47 1.22 
Nurse (GP Practice) Visits 
No. visits 104 1.93 8.83 118 0.71 1.32 
Occupational therapy  
No. visits 104 0.15 0.70 118 0.05 0.55 
Pacemaker 
No. visits 104 0.06 0.59 118 0.08 0.39 
Physiotherapy (home) 
No. visits 104 0.05 0.32 118 0.00 0.00 
Physiotherapy  
No. visits 104 0.05 0.20 118 0.02 0.11 
Wound clinic 
No. visits 104 0.06 0.28 118 0.03 0.15 
*discharged to convalescence/long term care/acute hospital instead of home 
 
 
Adjustment method 
 
To account for differences in baseline utility values, as well as skewness, censoring and confounding in cost 
data, linear regression models were used to provide adjusted estimates of mean values.  Control variables used 
were age, sex, valve, EQ-5D-3L baseline value and treatment arm. The type of valve used for replacement was 
also controlled for, because it was used as a stratification factor in the randomisation.  
 
Incremental cost effectiveness analysis and sensitivity analyses 
 
Differences in estimated costs and EQ-5D QALYs between trial arms, using raw data with imputation, were 
tested using two-sample t-test with equal variances.   
 
Incremental cost-effectiveness ratios were also constructed using adjusted mean estimates of costs and QALYs 
using ‘seemingly unrelated regression’, to account for correlation between costs and effects at the patient-level.  
This regression technique relies on the multivariate normality of the group-specific mean costs and QALYs, and 
is valid where the individual costs and QALYs are skewed (Faria et al 2014, [9]). 
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Probabilistic Sensitivity Analysis (PSA) was used to characterise the uncertainty of input parameters and a 
bootstrap approach (with 1000 bootstrapped samples) was applied to estimate the precision of results. The 
probability that mini-sternotomy is cost-effective when compared to full sternotomy is presented, at varying 
willingness to pay (WTP) threshold values, using a Cost Effectiveness Acceptability Curve (CEAC) and 
incremental net monetary benefit. 
 
Deterministic sensitivity analyses and scenario analysis were used to explore the robustness of cost-
effectiveness results that adopted different methodological approaches or assumptions (see Table B6). Baseline 
characteristics were assessed using Chi square and rank sum test, to assess whether patients included in the 
complete case analysis were different from those outside the complete case analysis. 
 
 
Table B6. Summary of deterministic sensitivity and scenario analyses undertaken 
 
Sensitivity analyses Rationale  
 
1. Complete case analysis 
 
Only including respondents with no missing values across all variables and 
across follow-up; to check results in sample requiring no missing value 
imputation 
 
2. Excluding patients who died during primary 
admission 
Patients who died during primary admission were the main cost driver and 
required substantial surgical time and cardiac care; to assess whether excluding 
these patients would change recommendations. 
 
3. Excluding additional equipment cost required Assuming the additional equipment required for the surgeries already exists in 
the trusts;  
 
4. Excluding follow-up resource use To test the assumption that the cost difference between the two arms were 
accrued during primary admission, to allow comparison with literature that 
missed these costs, but still retain benefits as captured in other studies. 
 
5. Excluding follow-up resource use and utility data Data up to discharge had few missing values; also to assess impact of having a 
shorter cut-off time point for trial (as wider literature had) but provide a less 
biased analysis that measures benefits but not costs. 
 
6. Use SF-6D utility values  
 
SF-6D values used as an alternative construction for QALYs 
 
 
Results 
 
The comparison of mean costs per patient up to one year (see Table B7), using raw data with imputation, shows 
that mini-sternotomy was £1,714 more than median sternotomy although this was not statistically significant.  
The higher costs resulted from longer surgery time, additional equipment and longer time in critical care. EQ-
5D QALYs were very slightly higher in the mini-sternotomy arm compared with full sternotomy (difference 
0.0279), but this was not statistically significantly so (see Table B8), and there was no statistically significant 
difference in SF6D QALYs either.  Figures B1 and B2 illustrate the distribution of total costs and QALYs across 
the patients in the trial.  
 
Table B9 summarises the comparison of costs and QALYs. The additional cost of gaining an additional QALY 
using mini-sternotomy rather than median sternotomy when imputed using PMM method is £61,379 and the net 
monetary loss at a willingness to pay (WTP) of £20,000 is £1,155.  
 
Seemingly unrelated regression analysis of costs and QALYs, adjusted for baseline characteristics showed that, 
in terms of QALYS, mini-sternotomy was not statistically significantly different from full sternotomy. Table 
B10 also shows that the coefficient for cost was positive, indicating mini-sternotomy was more costly than full 
sternotomy and that this difference was statistically significant.  Mini-sternotomy is therefore dominated by 
median sternotomy.  The cost effectiveness plane for the analysis is illustrated in Figure B3. 
 
The probabilistic sensitivity analysis shows (see Figure B4) that, at a WTP per QALY of £20,000, there is a 
3.7% likelihood that mini-sternotomy is cost-effective compared with median sternotomy and that this 
likelihood rises to 5.1% at a WTP of £30,000/QALY.  The net monetary benefit of mini-sternotomy is negative 
across all WTP threshold values (Figure B5). 
 
 
 
 
30 
 
Deterministic sensitivity analyses (see Table B11) showed that mini-sternotomy was either dominated or had a 
huge ICER. The one exception to this was the complete case analysis (CCA-cost-effectiveness), which found 
mini-sternotomy to be cost-effective. The intervention cost less but also had slightly worse outcomes in this 
sample size, which was limited to only 90 cases. The result indicates a saving of £10,000 for a loss of one 
QALY. The sample is not representative of those with missing data and consisted a larger proportion of females 
than the sample outside the CCA-cost-effectiveness sample. The sensitivity analyses conducted using PSA 
(Table B12) consistently found full sternotomy to be a superior intervention to mini-sternotomy. The cost 
effectiveness planes for the sensitivity analyses are illustrated in Figure B6.  
 
 
Table B7: Comparison of mean costs (SD) per patient up to 12 months post-randomisation (with 
imputation) (UK pounds, 2015) 
 
  
  Full Sternotomy Mini-sternotomy 
Mean 
Unit cost Obs 
Mean 
cost/ 
patient SD Obs 
Mean 
cost/ 
patient SD 
Primary Admission Costs 
Additional surgical items               
Horizontal surgical saw £3,138.2 104 £0.0 £0.0 118 £3.1 £0.0 
Single use saw blade for mini-sternotomy £48.0 104 £0.0 £0.0 118 £48.0 £0.0 
Single use saw blade for full sternotomy £15.8 104 £15.8 £0.0 118 £0.0 £0.0 
Paediatric internal cardioversion paddles £161.7 104 £0.0 £0.0 118 £0.2 £0.0 
Reprocessing cost of defibrillator paddles for each surgery £2.4 104 £2.4 £0.0 118 £2.4 £0.0 
Internal paddle handle £670.0 104 £0.0 £0.0 118 £0.7 £0.0 
Cost of additional surgical items**   104 £16.52 £0.0 118 £52.0 £0.0 
Theatre £20.0 104 £3,823.8 £1,243.0 118 £4,422.2 £2,053.0 
Critical care (ITU) £1,274.9 104 £1,833.8 £3,023.2 118 £2,934.2 £5,029.9 
Cardiac ward £388.0 104 £2,743.7 £1,664.0 118 £2,676.3 £1,499.9 
Rehabilitation* £158.6 104 £384.2 £1,877.6 118 £263.4 £1,621.3 
Acute hospital* £388.0 104 £346.9 £1,918.9 118 £297.5 £1,971.3 
Physiotherapy (inpatient) £12.7 104 £74.5 £53.2 118 £75.2 £65.3 
Occupational therapy (inpatient) £12.7 104 £2.1 £7.3 118 £3.0 £8.7 
Subtotal (primary admission) - 104 £9225.7 £6510.8 118 £10723.9 £8850.2 
Post Primary Admission Costs 
Hospital Admission           
 
  
ITU £1,274.9 104 £0.0 £0.0 118 £32.4 £352.1 
General ward £103.0 104 £268.4 £1,395.4 118 £79.4 £329.5 
Cardiac ward £388.0 104 £149.2 £554.8 118 £463.6 £1,606.4 
Tests           
 
  
24 hour Blood Pressure Monitoring £61.5 104 £10.9 £32.0 118 £10.2 £69.5 
Radiography (chest) £3.5 104 £19.4 £30.9 118 £21.6 £29.5 
Computerised Tomography Scan  £122.3 104 £19.4 £58.6 118 £19.7 £59.8 
Echo TTE £83.9 104 £35.1 £55.2 118 £46.9 £66.6 
Echo TOE £128.5 104 £2.5 £25.2 118 £6.5 £24.3 
Echo Stress £128.5 104 £1.2 £12.6 118 £1.1 £11.8 
24 hour ECG £140.7 104 £18.3 £57.2 118 £22.7 £62.3 
12 hour ECG £140.7 104 £101.5 £119.6 118 £132.9 £165.0 
Exercise Tolerance Test £140.7 104 £9.5 £34.0 118 £8.9 £32.6 
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MRI scan £146.2 104 £3.5 £21.3 118 £9.3 £32.5 
Full Pulmonary Function Testing  £55.3 104 £3.2 £12.4 118 £1.6 £9.1 
Blood test £3.5 104 £0.0 £0.1 118 £0.0 £0.1 
Healthcare visits               
A&E visit £140.6 104 £18.9 £43.0 118 £33.4 £70.4 
Arrhythmia clinic £131.1 104 £2.5 £18.1 118 £0.0 £0.0 
Cardiac Rehabilitation £97.8 104 £104.4 £271.9 118 £33.6 £133.4 
Cardio Clinic £123.0 104 £57.4 £76.3 118 £63.6 £88.1 
GP Home Visits £45.0 104 £12.1 £28.9 118 £11.3 £30.4 
GP Visits £65.0 104 £129.7 £140.6 118 £141.3 £141.8 
Nurse (Specialist Community) Home Visits £19.4 104 £7.3 £20.6 118 £9.0 £23.6 
Nurse (GP Practice) Visits £14.5 104 £28.0 £127.7 118 £10.3 £19.2 
Occupational therapy (outpatient) £16.7 104 £2.5 £11.7 118 £0.8 £9.2 
Pacemaker £76.3 104 £4.4 £44.9 118 £6.1 £29.5 
Physiotherapy (home) £27.0 104 £1.4 £8.6 118 £0.0 £0.0 
Physiotherapy (outpatient) £16.1 104 £0.8 £3.4 118 £0.3 £1.9 
Wound clinic £54.9 104 £3.4 £15.2 118 £1.6 £8.3 
Subtotal (post-primary admission) - 104 £1014.9 £1777.5 118 £1168.2 £2077.9 
Drugs (total) - 104 £379.4 £548.2 118 £441.4 £976.7 
Total cost   104 £10,620.0 £7,623.8 118 £12,333.5 £9,864.2 
*discharged to convalescence/long term care/acute hospital instead of home 
**mean cost per patient estimated by assuming that the saw, paddle and handle have a twenty year life span and 
are used in 255 surgeries in every 5 years; NB: defib (paddle, handle and sterilisation cost) applicable in only 
30% of cases 
 
 
Table B8. Summary of utility values and QALYs  
 
  Full Sternotomy Mini-sternotomy 
EQ-5D Obs Mean Utility SD Obs Mean Utility SD 
Baseline  
104 0.6988 0.24 118 0.7793 0.18 
4 Days Post Operation 
104 0.3721 0.29 118 0.4430 0.28 
Discharge 
104 0.5815 0.23 118 0.5940 0.25 
6 weeks follow-up 
104 0.6930 0.21 118 0.7195 0.24 
6 months follow-up 
104 0.8272 0.22 118 0.8322 0.24 
12 months follow-up 
104 0.7584 0.29 118 0.8253 0.29 
EQ-5D QALYs 
104 0.7699 0.19 118 0.7978 0.21 
   
  Full Sternotomy Mini-sternotomy 
SF-6D Obs Mean Utility SD Obs Mean Utility SD 
Baseline  
104 0.6418 0.11 118 0.6802 0.12 
6 weeks follow-up 
104 0.6327 0.10 118 0.6356 0.14 
6 months follow-up 
104 0.7184 0.16 118 0.7332 0.19 
12 months follow-up 
104 0.6868 0.19 118 0.7058 0.23 
SF-6D QALYs 
104 0.6847 0.12 118 0.6989 0.16 
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Figure B1. Distribution of total cost 
 
 
 
 
Figure B2. Distribution of QALYs 
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Table B9. Comparison of costs and QALYS (raw data, with imputation)  
 
 
Full Sternotomy (n=104) Mini-sternotomy (n=114) 
 
Mean SD Mean SD 
Total costs over 12 months 
£10,620 £7,624 £12,334 £9,864 
Incremental cost at 12 months (MS-FS) - £1,714 
 
Total EQ5D3L QALYs 
0.7699 0.19 0.7978 0.21 
Incremental EQ5D3L QALYs (MS-FS) - 0.0279   
ICER - £61,379 
INMB at WTP of £20,000/QALY - -£1,155 
INMB at WTP of £30,000/QALY - -£876 
 
 
Table B10. Regression estimates of costs and QALYs 
 
Dependant variable:  EQ5D QALYs 
  Coefficient Std. Err. P value [95% Conf. Interval] 
Mini-sternotomy -0.0040 0.0245 0.87 -0.0520 0.0440 
Male 0.0250 0.0246 0.31 -0.0231 0.0732 
Age -0.0051 0.0014 0.00 -0.0078 -0.0024 
Baseline EQ-5D score 0.3037 0.0590 0.00 0.1880 0.4194 
Tissue valve 0.0794 0.0459 0.08 -0.0107 0.1694 
Constant 0.7391 0.1093 0.00 0.5249 0.9533 
Dependant variable:  Total Cost (£) 
  Coefficient Std. Err. P value [95% Conf. Interval] 
Mini-sternotomy 2010.22 1201.57 0.09 -344.82 4365.25 
Male -1275.52 1205.23 0.29 -3637.73 1086.70 
Age 98.32 67.58 0.15 -34.13 230.77 
Baseline EQ-5D score -983.50 2896.40 0.73 -6660.34 4693.33 
Tissue valve -853.43 2254.14 0.71 -5271.45 3564.60 
Constant 5704.71 5362.01 0.29 -4804.64 16214.06 
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Table B11. Deterministic sensitivity analysis (using difference MS - FS, adjusted for baseline)  
 
 
Obs 
Incremental cost 
over 12 months  
(MS-FS) 
Incremental QALYs 
over 12 months  
(MS-FS) 
ICER 
INMB at 
£20,000 
per QALY 
INMB at 
£30,000 per 
QALY 
Mean 
Std 
Error 
Mean 
Std 
Error 
Missing values imputed by 
PMM  
222 £2,010 £1,202 -0.0040 0.0245 Dominated -£2,089.26 -£2,128.78 
Using SF6D QALYs  222 £2,010 £1,202 -0.0017 0.0178 Dominated -£2,044.44 -£2,061.55 
Assuming there is no 
additional equipment 
required for the two 
procedures 
222 £1,975 £1,202 -0.0040 0.0245 Dominated -£2,053.73 -£2,093.26 
Excluding follow-up 
resource use 
222 £1,664 £1,060 -0.0040 0.0245 Dominated -£1,742.98 -£1,782.50 
Complete case analysis 90 -£150 £661 -0.0145 0.0334 £10,333.62 -£139.89 -£284.60 
Excluding patients who died 
during primary admission 
219 £1,408 £1,128 0.0172 0.0216 £81,905.62 -£1,064.40 -£892.46 
Including costs and QALY 
data only up to discharge 
222 £1,664 £1,060 0.0013 0.0009 £1,316,409.02 -£1,638.66 -£1,626.02 
 
Table B12. Probabilistic sensitivity analysis (using difference MS - FS, adjusted for baseline)  
 
 
Obs 
Incremental cost 
over 12 months  
(MS-FS) 
Incremental 
QALYs over 12 
months  
(MS-FS) ICER 
INMB at 
£20000 
INMB at 
£30000 
Mean 
Std 
Error 
Mean 
Std 
Error 
Missing values imputed by PMM 
and adjusted 
1000 £2,154 £36 -0.0122 0.0008 Dominated -£2,396.99 -£2,518.59 
Using SF6D QALYs  1000 £2,154 £36 -0.0075 0.0006 Dominated -£2,303.03 -£2,377.66 
Assuming there is no additional 
equipment required for the two 
procedures 
1000 £2,245 £40 -0.0096 0.0008 Dominated -£2,437.25 -£2,533.50 
Excluding follow-up resource use 1000 £1,835 £35 -0.0131 0.0008 Dominated -£2,096.58 -£2,227.15 
Complete case analysis 1000 -£111 £22 -0.0121 0.0011 £9,170.78 -£130.56 -£251.12 
Excluding patients who died during 
primary admission 
1000 £1,433 £32 0.0147 0.0007 £97,425.25 -£1,138.55 -£991.50 
Including costs and QALY data 
only up to discharge 
1000 £1,835 £35 0.0008 0.0000 £2,415,384.92 -£1,820.25 -£1,812.65 
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Figure B3. Cost effectiveness plane (using difference MS-FS, adjusted for baseline) 
 
 
B3.1 Using EQ-5D to estimate QALY 
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
6
0
0
0
-.2 -.1 0 .1 .2
£20,000 ICER
 
 
B3.2 Using SF-36 to estimate QALY 
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Figure B4. Cost-effectiveness acceptability curve (EQ-5D) 
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Figure B5. Net monetary benefit (controlling for baseline characteristics and missing data) 
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Figure B6. Sensitivity analyses using difference (MS - FS), adjusted for baseline 
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1. TRIAL OVERVIEW 
 
1.1. Background 
 
Aortic valve replacement (AVR) is the second most common cardiac surgical procedure 
in the UK (3436 patients in 2006/07 [1]).  As increasing numbers of patients are referred 
for AVR each year including a large proportion of older patients [9] operative strategies 
are required to hasten postoperative recovery without compromising surgical quality or 
patient satisfaction. 
 
A multitude of preoperative variables may influence a surgeon’s decision to modify the 
standard surgical approach toward less invasive strategies, but the primary determinant 
is likely to be the surgeon’s level of experience with such procedures. A majority of AVR 
procedures are thus far still performed through a full median sternotomy [9].  
 
The advantage of the full median sternotomy compared with less invasive techniques is 
that it affords more options for pump cannulation and myocardial preservation providing 
optimal access to the heart and major vessels. In general, full median sternotomy is well 
tolerated but, together with cardiopulmonary bypass, it is a potential contributor to 
complications in high-risk individuals and is commonly perceived with apprehension by 
patients and referring physicians [9].   
 
Different techniques have been proposed to create safer and less invasive AVR 
procedures, including percutaneous AVR techniques which are still very experimental 
and carry a high level of risk [9].  Performance of AVR through smaller incisions is an 
alternative approach which provides considerable psychological comfort to patients and 
may confer additional benefits in terms of improved recovery and reduced activation of 
inflammatory cascades.  Although actual results vary considerably among centres, the 
overall advantages of minimally invasive approaches have been reported to include less 
postoperative pain, improved cosmetics, less blood loss, fewer pulmonary and wound 
complications, and shorter length of stay [9].  
 
An upper mini-sternotomy has the potential to hasten postoperative recovery following 
isolated AVR, resulting in reduced lengths of hospital stay and improved patient 
satisfaction [3, 4, 5, 6, 9]. In a recently published randomised controlled trial, 93% 
patients who had an AVR procedure via a mini-sternotomy approach reported only 
minimal post operative pain compared to 97% who reported severe pain following full 
median sternotomy [4]. 
 
The scientific validity of a majority of published comparisons of MiniStern to conventional 
AVR is poor.  Most reports are from case series or non-randomised observational studies 
and none have been conducted in a UK NHS setting.  Only four small RCTs comparing 
MiniStern to conventional AVR [3, 4, 7, 8] have been identified. The RCTs all had small 
sample sizes ranging from 40-80 participants and reported post operative outcomes 
varied considerably. For example, reductions in hospital stay using MiniStern ranged 
from 0-55%.  The two largest published cohort studies [5,6] have suggested that hospital 
stay can be reduced by 16% and 25%, but these were observational studies. 
 
Thus, there is no robust evidence on which to base guidelines for AVR surgical 
approaches in the UK. 
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1.2. Study Design 
 
This proposed study is a pragmatic, prospective randomised controlled trial comparing 
upper mini-sternotomy (MiniStern) to full median sternotomy as a surgical approach to 
first time isolated aortic valve replacement (AVR). 
 
1.3. Primary Outcome  
 
The primary outcome will be total length of stay in hospital for the index AVR operation 
measured in days. Length of hospital stay has been chosen as the primary outcome 
because it can be easily measured and is a composite measure sensitive to the patient 
related outcomes we hope to improve by using mini-sternotomy – namely early 
mobilisation, reduced pain levels and reduced sternal wound complications.  We believe 
that if a patient is fit for discharge then a reduced length of hospital stay is an important 
outcome for them in terms of morale, satisfaction with treatment and health related 
quality of life.   
 
However we recognise that with a predominately older population, patients may have co 
morbidities and social factors that delay discharge so that length of stay is determined by 
these issues rather than by fitness for discharge.  Although randomisation should ensure 
that such co morbidities and social factors are equally distributed between study groups, 
potential confounding variables will be carefully recorded.  
 
1.4. Secondary Outcomes 
 
1.4.1. Operative Data 
 
These will be collected on the day of surgery and will include total theatre time, cross 
clamp time, cardiopulmonary bypass time, blood loss, blood transfusion, and skin to 
skin time. 
 
1.4.2. In-Hospital Data 
 
Fitness for discharge – Patients will be assessed independently by the multi-
disciplinary discharge team and the research nurse according to a formal discharge 
protocol (Annex 1). The research nurse will record the postoperative day when the 
patient was fit to be discharged home and the final discharge date and destination.  
 
Time to first mobilisation: defined as walking independently 
 
Time to extubation: total number of hours of intubation (to account for re-intubation) 
 
Time to mediastinal drain removal 
 
Postoperative pain levels: the hospital’s visual and numerical analogue scale to score 
pain will be administered daily until hospital discharge (Annex 2). 
 
Need for analgesia:  after extubation and when competent to self administer, all 
patients will have a patient controlled analgesia (PCA) pump of morphine  Until this 
time they will receive a continuous infusion of morphine . They will also receive 
regular Paracetamol (1g qds till the date of discharge) to reflect hospital pain 
management protocols. The total dose of all pump delivered analgesia will be 
calculated prior to discharge. Any adjunct/supplementary analgesia will also be 
recorded. Morphine intolerance will also be recorded. 
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Wound infection and requirement for antibiotics. Wound exudate will be swabbed for 
microbiological culture as per hospital protocol   Wound Infection will be assessed 
and defined according to the Health Protection Agency Protocol for the Surveillance 
of Surgical Site Infection version 4, July 2008 (Annex 4) 
 
Perioperative bleeding and blood transfusion: Blood loss during the first 12 hours 
after surgery will be recorded.  The blood transfusion requirement during the first 48 
hours after surgery in all cases will be recorded.  The threshold haemoglobin level 
below which blood transfusion will be triggered will be 8 g% or below, as per current 
hospital transfusion protocol. Haemoglobin will be measured as per current hospital 
transfusion protocol. 
 
1.4.3. Health Related Quality Of Life and Patient Satisfaction after Surgery  
 
Health related quality of life and patient satisfaction will be assessed at baseline, 6 
weeks, 6 months and 12 months following surgery using the SF-36 [11], CROQ-
CABG [12] and the EQ-5D [13] questionnaires.  
 
The EQ-5D will also be repeated at day 4, on discharge and every 6 months after 
year one until the study is completed.  
 
The CROQ-CABG questionnaire was designed for cardiac patients undergoing 
coronary artery bypass surgery and includes angina symptoms, reported impact of 
the heart condition on physical, psychosocial and cognitive functioning and pertinent 
post-operative sections on surgical chest wound and satisfaction with the heart 
operation. The only modification to the CROQ-CABG will be to remove questions 
related to arm and leg wounds that are specific to bypass grafting. The relatively large 
sample size of this study will allow us to validate the use of this modified 
questionnaire (CROQ-AVR) in AVR patients (Annex 3). 
 
1.4.4. Clinical Outcomes  
 
Heart function (LVEF) will be assessed by echocardiography at baseline, day of 
discharge and 6 months post surgery. 
 
Respiratory function (FEV1) will be assessed by hand held spirometry at baseline; 
day of discharge; 6 weeks and 6 months. 
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1.5. Schedule of Events 
 
 
 
Details Pre 
Admission 
Pre-op 
day 
/operation 
day  
Day 1  
post 
op 
Daily 
checks 
Day 4  
post op 
Day of 
discharge  
6  
weeks 
Routine 
6  
months 
Research 
12  
months 
Telephone 
 
Patient screened 
and given PIS by 
surgeon 
X U                
 
Telephone follow 
up by Research 
Nurse 
X                 
 
Assessment of 
inclusion/exclusion 
criteria 
X U                
 
Informed consent X U                
 
HRQoL 
assessment  
SF-36, CROQ-AVR,  
EQ-5D 
(EQ-5D repeated 6 
monthly to 36 
months) 
X  U     
X  
(EQ-5D 
only) 
X  
(EQ-5D 
only) 
X X X 
 
Spirometry X U       X X X   
 
Transthoracic 
Echocardiography 
(X) 
Routine 
( U) 
Routine       X   X   
 
Randomisation   X               
 
In hospital routine 
data collection  
  X X  X  X  X        
 
Pain and analgesia 
assessment  
  X X X X X X     
 
Wound and 
Antibiotic 
Assessment  
  X X X X X X     
 
Fitness for 
discharge 
assessment 
(length of stay in 
ICU, Total hospital 
stay) 
      X X X       
 
Adverse Event 
assessment and 
reporting (up to 36 
months) 
  X X X X X X X X 
 
Resource use data  
(up to 36 months) 
 
  X X X X X X X X 
 
X study procedure, (X) and (U) routine procedure, U study procedure for in-house 
urgent patients only
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Study Population 
 
 
1.6. Inclusion criteria 
 
 Age > 18 years at the time of surgery 
 Elective, first time, isolated Aortic Valve Replacement 
 Documented severe emphysema or COPD if the FEV1 or TLCO is >40% predicted 
 
 
1.7. Exclusion criteria 
 
 Documented poor LV function or LVEF less than or equal to 30% 
 Documented chest wall deformities 
 Documented severe emphysema or COPD if the FEV1 or TLCO is <40% predicted 
 Current BMI > 35 
 Concomitant cardiac surgery 
 Redo surgery 
 Median sternotomy indicated (includes inability to have a transoesophageal 
echocardiogram). 
 
1.8. Sample Size  
 
 Sample size is based on an audit of 252 patients undergoing AVR at Papworth 
Hospital NHS Trust in 2007/08 who had a mean hospital stay of 11.7 days (SD 6.2).  
From 4 published RCTs [3, 4, 7, 8] and two large cohort studies [5, 6] we estimate 
that, using mini-sternotomy, a 20% reduction in total hospital stay from 11.7 to 9.36 
days is plausible and clinically important.  
 
 To detect this level of change with 80% power and 2 sided alpha of 5% we would 
need a sample size of 110 patients per group or 220 in total. For hospital stay it is 
unlikely that there will be loss to follow up.  
 
1.9. Recruitment 
 
 
At the surgical clinic the local investigator or an experienced delegated representative will 
identify patients who are eligible for the trial, will discuss participation in the trial with the 
patient and, if they are interested, will give the patients a copy of the patient information 
sheet to take home. 
 
The research nurse will contact these patients at home by telephone to see if they are 
still interested in taking part and to talk about the study in more detail, answering any 
questions they may have.   
 
Most patients awaiting surgery attend a routine surgical clinic 1-2 weeks before their 
scheduled admission. Patients will have the opportunity to discuss the study again at this 
visit. For those who would like to participate, the research nurse will confirm eligibility and 
obtain written informed consent. Once consent has been obtained baseline tests will be 
completed. 
 
In-house urgent patients awaiting AVR after admission for other investigations will be 
approached by their surgeon or an experienced member of the research team who will 
introduce the study and give the patient a copy of the in-patient information sheet to read. 
The patient will have the opportunity to discuss the study with relatives and their care team.  
A member of the research team will later visit the patient on the ward to see if they are 
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interested in taking part and to talk about the study in more detail, answering any questions 
they may have.  We will aim to give in-house urgent patients at least 24 hours to consider 
whether or not they would like to take part. For those who would like to participate, the 
research nurse will confirm eligibility and obtain written informed consent. Once consent has 
been obtained baseline tests will be completed. 
 
 
1.10. Proposed Recruitment and schedule (updated 14 June 2012, ) 
 
 
 
 
 
 
Predicted recruitment was originally based on randomisation of 10-11 patients per 
month, this has been revised and the predicted (new) randomisation rate is 6 patients 
per month. 
 2. Randomisation 
 
Eligible patients who fulfil the inclusion/exclusion criteria and have provided full written 
consent after they have had sufficient time for discussion and consideration, will be 
randomised (in a 1:1 ratio) to receive either their routine AVR using a full median 
sternotomy  approach or AVR using upper limited sternotomy performed in J-shape into 
the right 4th intercostal space. 
 
Patient allocations will be computer generated by the trial statistician and will be in 
random permuted blocks of variable lengths, stratified by surgeon and by type of valve 
(bioprosthetic or mechanical).  
 
On the day of their cardiac surgery, a member of the surgical team/research nurse will 
register the participating patient with the R&D unit by telephone. Patient details, surgeon 
and planned AVR procedure will be recorded by R&D personnel who are not otherwise 
directly involved with the trial. Once this registration is complete the group allocation will 
be released to the surgical team and perfusionists. 
 
It will not be possible to blind patients or the surgical and clinical team to the surgical 
approach used for the study. However the outcomes of ‘fitness for discharge’, pain, 
wound infection and health related quality of life will be collected by trained research 
staff, not involved in routine care, using standardised protocols. 
 
3. Procedure 
 
3.1. Mini-sternotomy procedure 
The patient is positioned supine in the operating table with a sandbag between the 
scapulae. The skin incision is made starting half way down the manubrium downwards 
for 8 cm.  Skin flap is then raised upwards and the sternum exposed till the 4th intercostal 
space.  The manubrium is divided in the midline using a vertical saw from the manubrium 
downward and then into the right 4th intercostal space.  The thymus is then divided in the 
midline and pericardium opened exposing the ascending aorta, aortic root, right atrial 
appendage and the right ventricular infundibulum.   
 
3.2. Procedures are common to both trial groups 
The patient is fully heparinised with standard dose of heparin.  The aorta is then 
cannulated using a wired flexible aortic cannula of suitable size.  The right atrial 
appendage is cannulated using a flat venous cannula and cardiopulmonary bypass is 
instituted.  The cardioplegia cannula and right superior pulmonary vein vent is inserted as 
standard, aorta cross-clamped and cardioplegia administered. The aorta is then incised 
open in an oblique or transverse fashion, the diseased valve excised and annulus 
decalcified.  An aortic valve prosthesis of suitable make (tissue or mechanical) and size is 
then inserted.  The aortotomy is then closed, heart de-aired and patient weaned off 
cardiopulmonary bypass in standard fashion.  Drains are inserted into the mediastinum 
and right pleura and pacing wires to the right atrium and ventricle. 
 
3.3. Conversion from mini-sternotomy to full-sternotomy  
Conversion to full-sternotomy will be done without hesitation if, after opening the 
pericardium, access to the aortic root proves difficult (~5% of cases).  All patients will 
have a transoesophageal echocardiogram in theatre at conclusion of the operation, 
before the chest is closed to confirm perfect valve implantation and function of the 
prosthesis.
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4. Patient follow up 
 
4.1. Follow up visits and Travel expenses (see also section 1.5) 
 
Patients will be assessed by our research nurse daily while in hospital to assess pain; 
drug use; wound status; bleeding; level of mobilisation and respiratory function.  
Following discharge patients will be assessed after 6 weeks at a routine clinic 
appointment, at 6 months during a research visit to the hospital and at 12 months using 
postal questionnaires or telephone interviews. Patient travel expenses, including parking 
charges will be reimbursed for the six month research visit. 
 
4.2. Adverse Events and Serious Adverse Events 
 
4.2.1. Defining Adverse Events 
 
Adverse Event (AE) 
The definition of an adverse event is: ‘Any untoward medical occurrence in a patient 
which does not necessarily have a causal relationship with this treatment’. This 
includes ‘any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the study treatment’. This 
may include, for example, a cold or an accident. 
 
Serious Adverse Event (SAE) 
The definition of a serious adverse event is one that fulfils at least one of the following 
criteria: 
 Is fatal- results in death  
 Is life threatening 
 Requires inpatient hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
 Medically significant or requires intervention to prevent at least one of the 
outcomes listed above  
 
SUSAR 
 
The definition of a suspected unexpected serious adverse reaction (SUSAR) is a 
serious adverse event that is thought to be possibly or definitely related to the study 
treatment. 
 
Expected adverse events 
 
Expected adverse events following AVR surgery (using either surgical approach) will 
include but are not limited to abnormal mental status, atrial fibrillation, atrial flutter, 
other cardiac arrhythmias, aortic dissection,  bleeding events surgical or non-surgical,  
cardiac arrest; cardiac failure, cardiac surgical complications; cardiac tamponade; 
death,  endocarditis,  invasive line infections, hospital acquired infections,  
neurological event (and consequences) exacerbation of existing/concomitant 
conditions, gastro-intestinal complications,  haemothorax, , multi-organ failure, 
myocardial ischaemia/infarction, pericardial effusion, perivalvular leak, pleural 
effusion, pneumothorax, pulmonary oedema, renal compromise or failure, respiratory 
compromise or failure, respiratory infection,  sepsis,  thrombo-embolic event, 
sternotomy wound infection. 
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Recording Adverse events 
 
All events meeting the definition of an adverse event will be collected and reported 
from the start of surgery until hospital discharge.  All SAEs will be recorded until the 
subject has completed the trial. 
 
 Documenting of adverse events is the responsibility of the Principle Investigator 
and Clinical Research Nurse 
 Standard documentation for reporting AEs for MiniStern at Papworth will be 
available in the trial site file  
 At each visit or study assessment, adverse events that have occurred since the 
previous visit will be elicited from the patient. The event will be detailed in the 
patient’s notes, as source document verification, including the start date (if known) 
and the end date.  
 Any treatment/medication given for the event, including the dates the 
treatment/medication was commenced and the date it was stopped/changed will be 
documented. 
 All research staff in contact with patients are responsible for noting adverse events 
that are reported by the patient and making them known to the Principle 
Investigator and Clinical Research Nurse 
 Events that are ongoing at the final study visit will be followed up as clinically 
indicated. 
 
4.2.2. Reporting Adverse events 
 
 All serious adverse events (SAEs) and suspected unexpected serious adverse 
reactions (SUSARs) will be documented as above using the appropriate reporting 
documentation and must be reported to the Sponsor within 24 hours of the Chief 
Investigator/Clinical Research Nurse being aware. 
 SUSARs must be reported to the Sponsor within 24 hours of the Chief 
Investigator/Clinical Research Nurse being aware. 
 SUSAR reports will be submitted to the REC by the sponsor within 14 days 
 Expected SAEs will be reported to the LREC in the annual REC report 
 Completed SAE forms will be stored with the patient’s study documentation. A 
photocopy should also be filed in the investigator site file. 
 
 
5. Data Collection and auditing 
 
5.1. Case Report Form Completion 
 
The clinical research nurse will record all trial data on a series of pre-prepared case 
report forms (CRFs). These forms will be returned to Papworth R&D unit.  The R&D unit 
will be responsible for data monitoring and quality control. A data quality and scanning 
officer will check the HRQoL data for missing values and prepare this data for analysis. 
 
5.2. Source Documentation 
 
The investigator/clinical research nurse will maintain source documents (patient’s hospital 
case notes) for each patient in the study. A copy of the consent form and patient 
information sheet will be filed in the patient’s case notes. All information in the CRFs, 
apart from the questionnaires, must be traceable to and consistent with the source 
documents in the patient’s hospital case notes (Ref. ICH/GCP 4.9.2).  
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5.3. Errors and Corrections 
 
Any change or correction to CRF should be dated, initialled, and explained (if necessary) 
and should not obscure the original entry. 
 
5.4. Storage of Documents 
 
CRFs will be kept in a locked filing cabinet or a locked room. 
 
5.5. Monitoring and Audit 
 
The project data will monitored by R&D Unit personnel independent of the trial. The first 
two patients will be monitored in full. Thereafter, one patient a month will be monitored up 
to a total of 10% of study patients, for consent, inclusion and exclusion criteria, adverse 
event reporting and primary outcome data. 
 
 
6. Data Analysis 
 
6.1. Statistical Analysis 
 
All statistical analyses and reporting will comply with CONSORT guidelines [14] where 
possible. For all outcomes all patients will be included in the analysis in the group to 
which they were randomised (ITT). Initial length of stay will be compared using the 
Student-T test since, although hospital stay is not normally distributed, the Central Limit 
Theorem suggests that means will have approximately Normal distribution, provided the 
sample is large. Time to all cause death will be explored using Kaplan- Meier curves. 
Pain, health related quality of life scores and the EQ-5D utility score will be compared 
using Likelihood Ratio Tests from linear regression models including baseline levels and 
treatment group. Repeated measures and time ordering will be modelled appropriately. 
For patients who die or are lost to follow up multiple imputation methods will be used 
based on regression predictions. Details of these analyses will be finalised when the 
pattern and amount of missing data is known. 
 
6.2. Economic Analysis 
 
An NHS perspective will be adopted for the economic analysis. The analysis will be 
consistent with the NICE reference case (Methodology Guidelines 2008 [15]). For both 
groups patient-specific resource use data will be collected until all patients have 
completed 12-months post-randomisation. 
 
The average cost of initial cardiac surgery will be based on the capital cost of equipment, 
variable costs, staff and overhead costs. Staff and overhead costs will be allocated 
according to theatre time and annual patient throughput. Variable consumable costs (e.g. 
blood products, IV heparin) will also be recorded prospectively on a per patient basis. 
 
Resource use will be monitored from surgery to 36 months post-randomisation and 
information collected on readmissions to hospital, further cardiac procedures, GP and 
outpatient visits and cardiac-related medication. Patients will be asked to record 
medications taken, inpatient and outpatient visits and any procedures on a standard 
questionnaire to be administered with the EQ-5D. Patient responses will be validated 
against hospital and primary care records. Unit costs will be taken from the hospital 
accounting system for each participating centre and nationally published estimates [16, 
17]. 
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At baseline, day 4, on discharge, 6 weeks, and 6 monthly thereafter (maximum 36 
months) post surgery all patients will be asked to complete the EuroQoL questionnaire. 
The social tariff for the EQ-5D, as estimated by Dolan et al will be applied to each 
patient’s self-reported classification in order to calculate utility values [13]. Using actual 
rather than nominal times of assessment and assuming a linear change in values 
between time points, patient-specific utility curves up to 12-months post randomisation 
will be calculated. A value of zero will be applied at the date of death for those patients 
who died. 
 
The QALYs experienced by each patient to 12-months post randomisation will be 
calculated as the area under their utility curve to 12-months or time of death, whichever 
occurs first. In order to adjust for differences in baseline utilities a linear regression will be 
fitted to the utilities post treatment, with baseline utility and treatment group as 
explanatory variables. Treatment effects will be taken from the treatment group 
coefficient of this regression. For patients who do not complete all EuroQoL/resource use 
measurements and are censored, the methods of Willan and Lin [18] will be used to 
estimate mean QALYs and costs. The incremental cost-effectiveness ratio (ICER), 
calculated as the ratio of the difference in costs and QALYs, will be estimated using the 
sample means. In order to generate confidence intervals without assuming any 
parametric form for the distribution of the costs, bootstrapping will be used to resample 
patients and repeat the calculations described above at least 1000 times [19].  
Measurements will be summarised as the mean and 95% confidence interval, estimated 
using bootstrapping. The bootstrap samples for the treatment comparison will also be 
plotted on the cost-effectiveness plane. In addition, cost-effectiveness acceptability 
curves (CEAC) for these comparisons will be plotted. The CEAC plots the probability that 
a procedure is cost-effective for differing values of a QALY.  Sensitivity analysis will be 
used to explore the impact of the deterministic variables within the economic analysis 
(e.g. unit cost estimates and discount rate).  
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7. Management & Governance   
 
Overall project management will be taken on by Papworth R&D Unit who will also assume 
Sponsorship responsibilities of behalf of Papworth Hospital NHS Foundation Trust. The R&D 
Unit has an established track record of managing clinical trials including several national 
multi-centre surgical RCTs.    
 
A Trial Management Protocol, based on the R&D Unit’s standard template, will be used to 
guide and inform management of the trial. The trial will be conducted to the highest 
standards and will be compliant with all Statutory and Regulatory requirements including the 
Research Governance Framework and GCP. A signed delegation log will clarify individual 
responsibilities. 
 
The Trial Manager will assume day-to-day responsibility for the trial. They will meet at least 
monthly with the Chief Investigator and also with the Senior R&D Manager and weekly with 
the Trial Nurse. These meetings will review progress against timelines, troubleshoot, review 
financial matters and ensure timely reporting to internal (R&D Committee) and external (e.g. 
West Anglia CLRN) groups.  
 
R&D Unit personnel independent of the trial will undertake monitoring and audit as described 
in section 6.5. 
 
An independently chaired Trial Steering Group will meet at least six monthly and an 
independent Data Monitoring and Ethics Committee will meet annually. Both will have patient 
representatives. 
 
7.1. Trial Steering Group (TSG) 
 
The TSG will monitor the progress of the trial in relation to the stated milestones and the 
interim and overall objectives and instigate any remedial actions. It will also review any 
relevant information from other sources and implement recommendations from the Data 
Monitoring and Ethics Committee (DMEC). The TSG will be responsible for reports to the 
NIHR, REC and WACLRN. 
 
7.2. Data Monitoring and Ethics Committee (DMEC) 
 
A separate Data Monitoring and Ethics Committee (DMEC) will also be convened as 
nominated by the TSG at their first meeting. The DMEC will meet annually but will be in 
regular contact to view the data and the results of any interim analysis and to instruct un-
blinding if necessary. The DMEC membership will include a clinician, a statistician and a 
health economist independent of the TSC, the study and the Chief Investigator.  
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Annex 1   
 
Discharge protocol for patient after aortic valve replacement: 
 
After aortic valve replacement, generally patients are considered fit to be discharged once 
they satisfy the following criteria: 
 
Pacing wires are removed. 
Dependable cardiac rhythm is present. 
Drains are removed and acceptable post-drain removal chest x-ray. 
Patient’s body weight is back to preoperative body weight or below.  
Patient mobilises well and ambulates without assistance. The patient should be able to walk 
(with mobility aid if required but unassisted) 80 metres on the flat and up and down a flight of 
stairs if they have stairs at home. 
Anticoagulation clinic arrangements are made in the local hospital. 
Occupational therapy and Physiotherapy clearance obtained. 
 
Social factors like lack of help at home, domestic and financial issues, delays in arranging 
hospital transport, delays in inter-hospital transfer, delay organising occupational health 
personnel visits to assess patient’s residence etc might contribute to delays in hospital 
discharge.  Hence, we have decided to have the day of “fit to be discharged” as treatment 
time in hospital for patients included in this trial. 
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Annex 2 Visual and numerical analogue pain score 
 
Annex 3 CROQ-AVR questionnaires  
 
Annex 4 Health Protection Agency Protocol for the Surveillance of Surgical Site Infection 
version 4, July 2008 
CONSORT 2010 checklist Page 1 
 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
 
Section/Topic 
Item 
No 
 
Checklist item 
Reported 
on page No 
Title and abstract    
 1a Identification as a randomised trial in the title   1  
 1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)   6  
Introduction    
Background and 
objectives 
2a Scientific background and explanation of rationale   7-9  
2b Specific objectives or hypotheses 8 
Methods    
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio   8  
 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons NA 
Participants 4a Eligibility criteria for participants   8  
 4b Settings and locations where the data were collected   8-9  
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
10-11 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9-10 
 6b Any changes to trial outcomes after the trial commenced, with reasons   NA  
Sample size 7a How sample size was determined   8  
 7b When applicable, explanation of any interim analyses and stopping guidelines   13  
Randomisation:    
Sequence 
generation 
8a Method used to generate the random allocation sequence   9  
8b Type of randomisation; details of any restriction (such as blocking and block size)   9  
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
9 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
9 
CONSORT checklist
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Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
NA 
 11b If relevant, description of the similarity of interventions   NA  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes   12-13  
 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses   12-13  
Results    
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
14 and Fig 1 
13b For each group, losses and exclusions after randomisation, together with reasons   14 and Fig 1  
Recruitment 14a Dates defining the periods of recruitment and follow-up   14  
 14b Why the trial ended or was stopped   14  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group   Table 1  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
14, 12 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
14-16 and 
  figures  
 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended   14-16  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
appendix 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 15,16 and 
  appendix  
Discussion    
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses   18-19  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings   18-19  
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence   16-18  
Other information    
Registration 23 Registration number and name of trial registry   2  
Protocol 24 Where the full trial protocol can be accessed, if available   Online  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 1 
CONSORT 2010 checklist Page 3 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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Not meeting inclusion criteria, n = 667  
Concomitant surgery n=301 
BMI >35 n=112  
 Clinical reason/Co-morbidity n=66  
Poor LV n=21  
COPD n=9  
Chest deformity n=7 
Administrative reasons=68  
Consented for other trial n=14  
Did not have surgery n=28 
Referring Cardiologist request n=7  
Unsuitable for TOE n=9   
Unable to consent/language difficulties 
n= 10 
Too young n=1 
Died pre operatively n=4 
Referred for TAVI n=18 
For Perceval valve n=2 
 
 
6 month follow up n=101 
Withdrawn/Lost to follow-up n=7 
Missed n=6 
Died n=4 
 
 
 
6 week follow up n=105 
Withdrawn/Lost to follow-up n=3 
Missed n=6 
Died n=4 
 
 
Allocated to MS, n =118  
Received allocated intervention n=104 
Conversion to full median sternotomy n=6 
 Aorta inter positional graft required n=1 
 Intraoperative injury requiring CABG n=2 
 Aortic root replacement required n=1 
 Calcified aorta n=1 
 Bleeding from aortic root n=1 
Did not receive allocated intervention n=8 
  FS indicated as ARR required n=1 
Ineligible for trial, underwent FS n = 1  
 Unable to have TOE post randomisation n=4 
Correct equipment unavailable n=2 
 
6 week follow up n=96 
Withdrawn/Lost to follow-up n=3 
Missed n=4 
Died n=1 
 
Assessed for eligibility, n=1024 
Declined trial participation n=72 
Training cases n=42 
                              Closed to recruitment n=11 
Screen Fail =677 
 
 
12 month follow up n=98 
Withdrawn/Lost to follow-up n=8 
Missed n=5 
Died n=7 
 
 
 
12 month follow up n=82 
Withdrawn/Lost to follow-up n=6  
Missed n=12 
Died n=4 
 
 
 
 
6 month follow up n=93 
Withdrawn/Lost to follow-up n=5 
Missed n=4 
Died n=2 
Allocated to FS, n=104 
Received allocated intervention n=103 
Withdrawn pre-operatively n = 1 
RANDOMISATION 
n= 222 
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PATIENT INFORMATION SHEET
PART 1
L Study title: The MiniStern Trial 
- 
A Pragmatic, Prospective, Randomised, Gontrolled
Trial Comparing Upper MiniSternotomy to Full Median Sternotomy as a Surgical
Approach for Aortic Valve Replacement
Ghief lnvestigator: Mr Sukumaran Nair, Consultant Cardiothoracic surgeon
2. lnvitation paragraph
We would like to invite you to take part in a research study called the MiniStern Trial.
Before you decide you need to understand why the research is being done and what it will
involve for you. Please take time to read the following information carefully. Talk to others
about the study if you wish.
Please ask if there is anything that is not clear or you would like more information. Further
information can be obtained from the Therapeutics & Cardiac Research Team, Freeman
Hospital, Newcastle upon Tyne, NE7 7DN. Tel: 0191 2137201.
3. What is the purpose of the study?
Aortic valve replacement (AVR) is an operation used to relieve the symptoms of a narrowed
or leaky heart valve and reduce the risk of future heart failure. Patients may have symptoms
such as shortness of breath, chest pain, dizziness or fainting spells. AVR is the second most
common open heart operation in the UK and increasing numbers of patients are referred for
AVR each year.
During an AVR operation the chest is cut open via the breastbone (or sternum); this incision
is called a sternotomy. A heart bypass machine is used to keep the blood circulating while
the heart is stopped for surgery. The surgeon then opens the aorta (the big artery coming
out of the heart) takes out the old valve and stitches in the new one. The aorta is closed, the
heart is restarted, the bypass machine is stopped and the sternotomy wound is closed.
The aim of this study is to compare two different techniques for opening the chest for AVR.
We would like to find out if there is any difference in the length of time patients stay in
hospital after each of these techniques and also to find out if a smaller incision can help to
speed up recovery after the operation but maintain the overall success of the surgery.
4. What are the techniques being compared?
Conventional AVR surgery requires the surgeon to open the chest wall via an incision all the
way from the collar bone to the bottom of the breast bone; this is called a full median
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sternotomy. More recently a technique called mini-sternotomy has been used, which
involves making a much shorter incision in the chest.
Full Median Sternotomy Mini-sternotomy
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A few research studies have already compared mini-sternotomy to full median sternotomy
for AVR but they have only studied small numbers of patients and none of the studies were
carried out in the UK. These studies suggest that mini-sternotomy AVR may be associated
with less post operative pain, less blood loss, fewer lung and wound complications and a
shorter length of hospital stay than full sternotomy. However, they also suggest that the
operation may take longer, and for about 1 in 20 patients it will be necessary to open the
chest wall further to complete the operation successfully.
At present, surgeons in the UK offer the mini sternotomy procedure to some patients but not
others. Some patients accept it and others do not. Neither the surgeons nor the patients truly
know if mini sternotomy can help to reduce hospital stay or improve recovery after an AVR
operation. This study is designed to answer this important question.
The MiniStern trialwill compare patients having an AVR operation with a full median
sternotomy to those having an AVR operation using mini-sternotomy. To make it fair, the two
groups must be similar. We can achieve this by putting patients in one or another group at
random. This is like tossing a coin and is done by a computer. This type of study is called a
randomised study. lf you take part in the MiniStern trial you will have a 1 in 2 chance (fifty-
fifty) of getting the mini or the median sternotomy procedure.
5. Why have I been invited?
Your surgeon has identified you as someone who is going to have their first AVR at the
Freeman Hospital.
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6. Do I have to take part?
No. !t is entirely up to you to decide if you want to take part.
-3-
Your surgeon will have spoken to you about the study when you came to clinic and will have
given you this information sheet to take home. You can then discuss the study with your GP,
relatives and friends. A member of the research team will call you at home to see if you are
interested in taking part and to talk about the study in more detail, answering any questions
you may have.
About 2-4 weeks before your AVR surgery you will attend a routine pre-admission clinic at
the hospital. This will again give you the chance to ask for more information from your
surgeon and research nurse or coordinator.
lf you do not want to take part you will have your AVR as planned, using full median
sternotomy, and will continue to be looked after by your surgeons in exactly the same way.
lf you are happy to participate you will be asked to sign the consent form that is attached
to this information sheet.
You are free to withdraw at any time without giving a reason. This wil! not affect the
standard of care that you receive.
7. What will happen to me if I take part?
At Pre-admission clinic: Our research nurse will ask you to perform some simple breathing
tests and to complete some standard quality of life questionnaires. These will as far as
possible be incorporated into your normal schedule of activities for the visit and will add no
longer than an hour to the visit. These procedures will be repeated again at regular intervals
after your surgery.
Before your operation: When you come in for your operation, our research nurse will visit
you and ask you to confirm that you are stillwilling to participate in this study. The nurse will
then check with you if there have been any changes to your health and well being since you
were assessed at the pre-admission clinic.
On the day of your surgery, the surgical team performing your operation will contact the
Research Unit at Papworth hospital to find out whether you have been randomised to mini or
full sternotomy and your operation will continue using the appropriate technique.
After your operation: When you wake up your wound will be covered by a dressing but you
will be able to find out which technique you were allocated to by asking your nurse or
surgeon.
You will be given pain relief medicatlon which will be delivered by a continuous drip into your
vein (this is routine practice after all AVR operations). When you are awake and able your
nurses will teach you to use a special PCA (patient controlled analgesia) pump so that you
can control delivery of pain medication as you require. PCA pumps would normally be used
after mini-sternotomy but for this study they will also be provided after full sternotomy. When
you no longer require the PCA pump you will be given Paracetamoltablets as required.
The research nurse will visit you, as far as possible each day, to assess your pain and to
make a record of the pain medication you are taking. She will also look at your wound and
collect data about this too.
Paaa a af 7 The l\/liniStcrn Triql PIS rrorcinn 2Q (.)ntnhar 2i1a,
IR&D reference number: P01292 -4-
On day of discharge from hospital: You will have had a routine transthoracic
echocardiogram or 'Echo' before your operation. This is performed on the surface of your
chest and is like an ultrasound. The Echo assesses the functioning of your aortic and other
valves and strength and capability of your pumping chambers in your heart. This will be
repeated prior to your discharge from hospital. You will also be asked to repeat the simple
breathing test and a one page quality of life questionnaire.
6-8 weeks after your operation: The 6-week visit is a routine hospital visit. ln addition to
your routine follow up you will be asked to repeat the breathing test and the quality of life
questionnaires. The research nurse will also ask you how you are feeling and if you have
had any side effects from the operation. She will assess your pain levels, your wound
healing and any medications you have been taking.
6 months after your operation: At 6 months after the operation we will ask you to come to
the hospital again for an extra research visit. At that visit the research nurse will see you to
perform the breathing/lung function test, assess your general health and well being,
checking for any side effects, and will also have arranged for you to have another'Echo'to
assess your heart and new valve function. She will also give you the questionnaires about
your quality of life and patient satisfaction to complete. We will pay your travel expenses,
including parking charges for this extra research visit.
After 12 months the research nurse or a member of the team will be in touch by telephone
to discuss your health and how you have been feeling or if you have had any side effects.
She will also either post the quality of life questionnaires or work through them with you over
the telephone, depending on what you would prefer. After this, the research team will contact
you by telephone or post every six months, for up to 3 years to find out how you are getting
on.
The findings of the study will be regularly monitored as the study proceeds. lf at any time we
find that one group is doing significantly better than the other, we will have answered the
question and the study will be stopped.
8. What are the possible disadvantages and risks of taking part?
The mini-sternotomy is not a new procedure and the surgeons involved in this study are all
experienced in conducting AVR surgery.
Performing a mini-sternotomy may lengthen your operation by about 30 minutes, because
access to the heart is slightly more difficult. There is no evidence that the risks from the
operation will be increased because the operation takes longer.
There is a potential risk with mini sternotomy AVR of not being able to access the heart as
well as can be achieved with full median sternotomy. However conversion to full median
sternotomy will be done without hesitation if access proves difficult.
The additional research visit at 6 months may be inconvenient. You will be reimbursed for
travel and parking costs associated with this additional-visit..
9. What are the possible benefits of taking part?
Your surgeon cannot guarantee that you will receive any personal benefit from participating
in this study. The benefits that you experience will depend on the results of the study and the
group that you are allocated to. lf the study shows that patients' hospital stay and quality of
life are improved by mini-sternotomy and you are randomised to this group then you may
benefit.
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lf you participate in this study you will have the advantage that your health will be monitored
more closely than patients who do not take part in the study. You will also be contributing to
the information we can give future patients having AVR operations.
10. What will happen to me when the research study stops?
Your doctors will continue to monitor your health according to routine practice.
11. What if something goes wrong?
Any complaint about the way you have been treated during the study or any possible harm
you might suffer will be addressed. Further detailed information is included in Part 2.
12. Will my taking part in this study be kept confidential?
Yes. All the information about your participation in this study will be kept confidential. The
details are included in Part 2.
13. Contact details:
lf you have any questions about this study please contact:-
Mrs Lesley Bremner Mr Sukumaran Nair
Research Nurse Consultant Cardiothoracic Surgeon and
Therapeutics & Cardiac Research Team Chief lnvestigator
Lesley.Bremner@nuth.nhs.uk Sukumaran.Nair@nuth.nhs.uk
Tel:0191 2137201 Tel:0191 2137702
Thank you for taking the time to read this.
This completes Part 1 of the lnformation Sheet.
lf the information in Part t has interested you and you are considering participating
please read the additional information in Part 2 before making a decision.
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PART 2
1. What if relevant new information becomes available?
The study will be overseen by an independent Committee. lts role is to check that the study
is run correctly and to ensure that patients remain safe.
lf this Committee or the research surgeons hear of relevant new information during the
course of this study, they will tell you about it and discuss whether you should continue in the
study.
lf the study is stopped for any reason we will tell you and arrange for your care to continue.
2. What will happen if I don't want to carry on with the study?
lf you wish us to stop collecting your medical information then we will do so. However we will
need to use the information collected up until the time that you decided to withdraw from the
study.
3. What if there is a problem?
lf you are concerned about any aspect of this study you should ask to speak to one of the
researchers who will do their best to answer your questions (contact details at the end of this
lnformation Sheet). lf you remain unhappy and wish to complain formally, you can do this
through the NHS Complaints Procedure.
lf something goes wrong and you are harmed during the study due to someone's negligence
then you may have grounds for a legal action for compensation against the hospital involved,
but you may have to pay your legal costs. The normal NHS complaints mechanisms will still
be available to you.
NHS hospitals are unable to agree in advance to pay compensation for non-negligent harm
(situations where no one can be blamed for what happened). However, NHS Trusts are able
to consider offering an ex-gratia payment in the case of a claim.
4. Will my taking part in this study be kept confidential?
All information that is collected about you during the course of this study will be kept strictly
confidential according to the Data Protection Act 1998. lt will be placed in a study file and
given a study number so that you cannot be identified personally. This anonymous
information will be used by members of the research team.
lf you join the study you also agree that certain members of the study team and
representatives of regulatory authorities can have access to your medical records (ie
information that will identify you personally). This will be necessary for your surgeon to
manage your treatment and for the study team and authorities to check that the study is
being carried out correctly. Your personal information is roulinely registered on national
databases and we will ask you to agree that researchers can have access to this information
so that they can keep in contact with you during the study.
All the people involved in this study have a duty of confidentiality to you as a research
participant and will ensure that nothing that could reveal your identity will be disclosed
outside the research site.
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lnformation on paper will be kept in locked filing cabinets and where possible behind security
coded, locked doors. Electronic information will be kept on computers that are protected by
passwords. Any information about you that leaves the hospitalwill be anonymous and
anything that could identify you (name, date of birth, address, hospital number) will be
removed and you will only be identified by a study code. When the study is reported to the
funding agency, published in medicaljournals or presented at conferences it will not be
possible to identify you personally.
With your consent, we will inform your GP that you are participating in this study.
5. What will happen to the results of the research study?
The results of the study will be published in medical journals, presented at national and
international medical conferences and described in reports submitted to the funding agency
and regulatory authorities. You will not be named or identified in any report of the study. You
may receive copies of these publications if you wish to.
6. Who is organising and funding the research?
The research is organised by Papworth Hospital and funded by the Research for Patient
Benefit Programme of the National lnstitute for Health Research. Your surgeon will not be
paid for including you in this study.
7. Who has reviewed the study?
The study was reviewed by the Research for Patient Benefit Programme reviewers and has
been given a favourable ethical opinion by Essex Research Ethics Committee.
Thank you for considering taking part in this study.
lf you decide to participate you will be asked to sign a consent form and will be given
a copy of this information sheet and the consent form to keep.
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The Freeman Hospital
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www. newcastle-ha:pita 1*.nhs,uk
Patient ldentification Number:
CONSENT FORM
Study title: The MiniStern Trial- A Pragmatic, Prospective, Randomised, Controlled Trial
Comparing Upper Mini Sternotomy to Full Median Sternotomy as a Surgical Approach for Aortic
Valve Replacement
Chief lnvestigator: Mr Sukumaran Nair
initial box
1. I confirm that I have read and understood the information sheet
dated 29 October 2013 (version 5) for the above study and
have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical
care or legal rights being affected.
3. I understand that sections of my medical notes and information
collected during the study may be looked at by responsible individuals
from regulatory authorities or from the NHS Trust where it is relevant to
my taking part in this research. I give permission for these individuals to
have access to my records.
4. I agree that researchers can have access to information about me that is
registered on national databases.
5. I consent to my GP being informed of my participation in this study.
6. I agree to take part in the above study.
Name of Patient Date Signature
Name of person taking consent Date Signature
When completed, 1 for patient; 1 for researcher site file (original); 1 to be kept with hospital notes
Please
T
I
T
T
r
r
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